NANOCARRIER COMPOSITIONS FORMULATED AND / OR COFORMULATED WITH PRODRUGS THAT INDUCES IMMUNOGENIC CELL DEATH (ICD) USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF

ICD-inducing prodrugs encapsulated in nanocarriers like liposomes and solid lipid nanoparticles address the limitations of current cancer treatments by enhancing immune response and reducing side effects, improving treatment efficacy for solid tumors.

JP2024542183APending Publication Date: 2024-11-13NAMMI THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024529181
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-18
Filing Date
2022-11-17
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current cancer treatments, particularly for solid tumors, face challenges with metastasis, chemotherapy resistance, and severe side effects, necessitating new therapeutic strategies that enhance immune response and reduce toxicity.

Method used

Development of ICD-inducing prodrug compositions encapsulated within nanocarriers, such as liposomes and solid lipid nanoparticles, which release immunogenic agents to trigger an immune response and target cancer cells while minimizing harm to healthy tissues.

Benefits of technology

The approach enhances the immune response against cancer cells, reduces side effects, and improves treatment efficacy for various tumor types by delivering ICD-inducing agents specifically to tumor sites, thereby increasing therapeutic utility and reducing systemic toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542183000001_ABST
    Figure 2024542183000001_ABST
Patent Text Reader

Abstract

Disclosed herein are formulated and / or co-formulated nanocarriers (e.g., LNPs and / or SLNPs) containing ICD prodrugs, as well as methods of making the nanocarriers. The ICD prodrug composition comprises a drug moiety, a lipid moiety, and a linking unit that induces immunogenic cell death (ICD). The ICD prodrugs can be formulated and / or co-formulated into nanocarriers to provide a method of treating cancer, immunological disorders, and other diseases by utilizing a targeted drug delivery vehicle.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 361,075, filed November 18, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] Statement of Rights to Inventions Made Under Federally Sponsored Research Not applicable.

[0003] FIELD OF THEINVENTION The invention described herein relates to prodrug compositions that induce immunogenic cell death (ICD) after the release of active inducers / inhibitors from the prodrug and nanoformulations that contain such prodrugs. Specifically, the invention relates to prodrug compositions that are formulated in nanocarriers (e.g., liposomes) and used as vehicles for cancer therapy in humans. The invention also relates to co-formulations of such prodrugs with other immunomodulators or prodrugs or various combinations thereof. The invention further relates to the treatment of cancer and other immunological disorders and diseases. [Background technology]

[0004] 2. Background of the Invention Cancer is the second leading cause of death in the world after coronary artery disease. Millions of people die from cancer each year, with well over half a million cancer deaths annually in the United States alone, and 1,688,780 new cancer cases diagnosed in 2017 (American Cancer Society). Deaths from heart disease have declined significantly, but those from cancer in general are increasing. Early in the next century, cancer is projected to become the leading cause of death, unless medical advances change current trends.

[0005] Some cancers stand out as having high mortality rates. Specifically, carcinomas of the lung (18.4% of all cancer deaths), breast (6.6% of all cancer deaths), colorectal (9.2% of all cancer deaths), liver (8.2% of all cancer deaths), and stomach (8.2% of all cancer deaths) are the leading causes of cancer deaths in the world at all ages and for both sexes (GLOBOCAN 2018). These and virtually all other carcinomas share a common lethal characteristic in that they metastasize from the primary tumor to distal sites, and almost without exception, metastatic disease is fatal. Furthermore, even cancer patients who survive their primary cancer at an early stage demonstrate a common experience of upheaval in their lives. Many cancer patients experience intense anxiety due to awareness of the possibility of recurrence or treatment failure. Many cancer patients also experience physical debilitation after treatment. Furthermore, many cancer patients experience a recurrence of their disease.

[0006] Although cancer therapy has improved over the past decades and survival rates have increased, the heterogeneity of cancer still requires new therapeutic strategies that utilize multiple treatment modalities. This is especially true in the treatment of solid tumors in critical anatomical sites (e.g., glioblastoma, squamous cell carcinoma of the head and neck, and lung adenocarcinoma), which may be limited to standard radiotherapy and / or chemotherapy. In any case, the adverse effect of these treatments is chemotherapy and radiotherapy resistance, which promotes locoregional recurrence, distant metastases, and second primary tumors, in addition to severe side effects that reduce the patient's quality of life.

[0007] Generally speaking, ICD is any type of cell death that elicits an immune response. ICD is in contrast to other forms of cell death (e.g., apoptosis, autophagy, and others) that do not elicit any response but rather mediate immune tolerance. ICD is characterized by an apoptotic morphology that maintains membrane integrity. See GARG, et. al., Int. J. Dev. Biol. 59: pp. 131-140 (2015). In addition, ICD is characterized by the secretion of damage-associated molecular patterns (DAMPs). In general, there are three main DAMPs that are exposed to the cell surface during ICD. The first one is calreticulin (CRT), one of the DAMP molecules that is normally present in the lumen of the endoplasmic reticulum, and is translocated to the surface of dying cells after induction of immunogenic death. There, it serves as an "eat me" signal for professional phagocytes. The second are surface-exposed DAMPs known as heat shock proteins (HSPs), namely HSP70 and HSP90, which further translocate to the plasma membrane under stress conditions. On the cell surface, they have immunostimulatory effects based on their interaction with several antigen-presenting cell (APC) surface receptors, such as CD91 and CD40, and also promote the cross-presentation of antigens derived from tumor cells on MHC class I molecules, which then triggers CD8+ T cell responses. The third DAMP characteristic of ICD is secreted HMGB1 and ATF. HMGB1 is considered to be a marker of late ICD, and its release into the extracellular space has been shown to be required for optimal antigen presentation by dendritic cells. It binds to several pattern recognition receptors (PRRs) expressed on APCs, such as Toll-like receptors (TLRs) 2 and 4. ATP, released during immunogenic cell death, when secreted, serves as a "find me" signal for phagocytes, inducing their attraction to sites of ICD. In addition, binding of ATP to purinergic receptors on target cells has immunostimulatory effects through inflammasome activation.DNA and RNA molecules released during ICD have been shown to activate TLR3 and cGAS responses in both dying cells and phagocytes. See GALLUZZI, et. al., Cell Death and Diff. (2018) 25:pp. 486-451.

[0008] Generally, two groups of ICD inducers are recognized in the art: Type I inducers cause stress to the endoplasmic reticulum (ER) only as collateral damage and primarily target DNA or chromatin maintenance machinery or membrane components; Type II inducers specifically target the ER.

[0009] ICD is induced by some cytostatic drugs, such as anthracyclines, oxaliplatin, and bortezomib, or by radiation therapy and photodynamic therapy (PDT). In addition, some viruses can be mentioned among other biological causes of ICD. Just as the immunogenic death of infected cells induces an immune response against infectious agents, the immunogenic death of cancer cells can induce an effective antitumor immune response through the activation of dendritic cells (DCs) and the resulting activation of specific T cell responses. This effect is used in antitumor therapy. See KRYSKO, et. al., Nat. Revs, Cancer 12(12):pp860-875 (2012) and SPISEK, et. al., Cell Cycle 6(16)pp. 1962-1965 (Aug. 2007).

[0010] Various drugs used to induce cell death are in use and are currently being evaluated as cancer therapies. Doxorubicin, among others, has been approved for medical use in the United States since 1974. Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. It inhibits the progression of topoisomerase II, an enzyme that relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after breaking the DNA strand for replication, preventing the DNA double helix from being released, thereby halting the process of replication. See TACAR, et. al., J. Pharm. & Pharmcol, 65, pp. 157-170 (2012).

[0011] Pegylated (MYOCET) and liposomal versions (DOXIL) of doxorubicin are also commercially available in the United States and other countries for the treatment of cancer and other diseases.

[0012] A prodrug is a pharmaceutical or compound that is metabolized (i.e., transformed in the body) into a pharmacologically active drug after administration. Rather than administering a drug directly, a corresponding prodrug is instead used to improve how the drug is absorbed, distributed, metabolized, and / or excreted. Prodrugs are often designed to improve bioavailability, for example, when the drug itself is poorly absorbed from the digestive tract. Prodrugs can be used to improve how selectively a drug interacts with cells or processes that are not its intended target. This reduces the harmful or unintended effects of the drug, which is particularly important in treatments such as chemotherapy that can have severe unintended and undesirable side effects. Prodrugs can therefore be considered as drugs that contain specialized non-toxic protecting groups that are used in a temporary manner to modify or eliminate undesirable properties of the parent molecule.

[0013] Finally, nanocarriers are nanomaterials that are used as a means of transporting another substance, e.g., a drug. There are many different types of nanocarriers. For example, nanocarriers include polymer conjugates, polymer nanoparticles, lipid-based carriers, and dendrimers, to name a few. Different types of nanomaterials are used in nanocarriers to allow hydrophobic and hydrophilic drugs to be delivered throughout the body. The ability to effectively deliver hydrophobic drugs in humans is a major therapeutic advantage of nanocarriers, since the human body is primarily composed of water. Nanocarriers are promising in the drug delivery process because they can deliver drugs to site-specific targets, allowing drugs to be delivered to certain organs or cells rather than others. Site specificity is a major therapeutic advantage, since it prevents drugs from being delivered to the wrong location. In addition, nanocarriers are particularly promising for use in chemotherapy, since they may help reduce the harmful broader toxicity of chemotherapy to healthy, fast-growing cells of the body. Because chemotherapy drugs can be highly toxic to human cells, it is important that they are delivered to the tumor without being released to other parts of the body.

[0014] From the above, it will be readily apparent to those skilled in the art that new treatment paradigms are needed in the treatment of cancer and other immunological diseases. By using novel prodrugs in conjunction with modern nanocarrier modalities, new disease treatments can be achieved with the overall goals of more effective treatment, reduced side effects, and higher therapeutic utility in the treatment of cancer, especially in solid tumors. In light of the current deficiencies associated with cancer treatment, it is an object of the present invention to provide new and improved methods of treating cancer, immunological disorders, and other diseases utilizing prodrugs encapsulated within nanocarriers. [Prior art documents] [Non-patent literature]

[0015] [Non-Patent Document 1] GARG, et. al., Int. J. Dev. Biol. 59: pp. 131-140 (2015) [Non-Patent Document 2] GALLUZZI, et. al., Cell Death and Diff. (2018) 25:pp. 486-451 [Non-Patent Document 3] KRYSKO, et. al., Nat. Revs, Cancer 12(12):pp860-875 (2012) [Non-Patent Document 4] SPISEK, et. al., Cell Cycle 6(16)pp. 1962-1965 (Aug. 2007) [Non-Patent Document 5] TACAR, et. al., J. Pharm. & Pharmcol, 65, pp. 157-170 (2012) Summary of the Invention [Means for solving the problem]

[0016] Summary of the Invention The present invention provides an ICD-inducing prodrug ("ICD prodrug") composition comprising an ICD-inducing agent, a lipid, and a biologically cleavable linker. In certain embodiments, nanocarriers comprising an ICD prodrug are formulated for use as a delivery modality for treating human diseases, such as cancers, including solid tumor cancers, as well as other immunological disorders. In certain embodiments, the nanocarriers comprise a lipid bilayer that can be incorporated into a drug delivery vehicle (i.e., a liposome). In further embodiments, the nanocarriers comprise solid lipid nanoparticles ("SLNPs"). In further preferred embodiments, the liposomes comprise cholesterol hemisuccinate ("CHEMS"). In further preferred embodiments, the liposomes of the present invention comprise stearic acid. In further preferred embodiments, the liposomes of the present invention comprise stearic acid and a hydrazone.

[0017] In further embodiments, the ICD prodrugs of the present disclosure include IC1 prodrugs.

[0018] In a further embodiment, the present invention includes a method of delivering an ICD-inducing agent to a tumor, the method comprising the steps of: (i) synthesizing an ICD prodrug; (ii) formulating the ICD prodrug of the present invention in a nanocarrier of the present invention; and (iii) administering the nanocarrier to a patient.

[0019] In another embodiment, the present invention comprises a method of delivering an ICD-inducing agent with one or more additional immunomodulatory agents to a tumor, the method comprising the steps of: (i) synthesizing an ICD prodrug; (ii) co-forming the ICD prodrug of the present invention with one or more additional immunomodulatory agents of the present invention in a nanocarrier; and (iii) administering the nanocarrier to a patient.

[0020] In another embodiment, the immunomodulatory agent comprises an A2aR antagonist, a PD-1 antagonist, a toll receptor agonist, a STING agonist, an IDO inhibitor, a CTLA4 inhibitor, a CD1D agonist, a TGFb inhibitor, and / or a prodrug thereof. Additionally, co-formulation with additional immunogenic cell death-inducing chemotherapeutic agents and / or prodrugs thereof is contemplated herein.

[0021] In another embodiment, the present disclosure teaches a method for synthesizing an ICD prodrug.

[0022] In another embodiment, the disclosure teaches a method for synthesizing an IC1 prodrug.

[0023] In another embodiment, the present disclosure teaches methods of formulating an ICD prodrug into nanocarriers, including but not limited to liposomes.

[0024] In another embodiment, the present disclosure teaches methods of formulating IC1 prodrugs into nanocarriers, including but not limited to liposomes.

[0025] In another embodiment, the present disclosure teaches methods of formulating IC1 prodrugs into nanocarriers, including but not limited to SLNPs.

[0026] In another embodiment, the present disclosure teaches methods of using the nanocarriers of the present disclosure to treat cancer, immunological disorders, and other diseases in humans. [Brief description of the drawings]

[0027] [Figure 1] Chemical synthesis of IC1 prodrugs. [Diagram 2] Synthesis scheme of ICD derivative prodrugs using carboxylic acid functionality. [Diagram 3] Synthesis scheme of ICD derivative prodrugs using alcohol functionality. [Figure 4] ICD derivative prodrug synthesis schemes with secondary amine, amide, or aniline functionalities. [Diagram 5] Characterization of SLNP-IC1 solid lipid nanocarriers. [Figure 6] Characterization of SLNP-IC1 solid lipid nanocarriers (zeta potential). [Figure 7] Characterization of SLNP-IC1-RGD solid lipid nanocarriers. [Figure 8] Characterization of SLNP-IC1-RGD solid lipid nanocarriers (zeta potential). [Figure 9] Characterization of SLNP-Dox solid lipid nanocarriers. [Figure 10] Characterization of SLNP-Dox solid lipid nanocarriers (zeta potential). [Figure 11] Characterization of SLNP-IC1-TR12 solid lipid nanocarriers. [Figure 12] Characterization of SLNP-IC1-TR12 solid lipid nanocarriers (zeta potential). [Figure 13] Serum stability / release kinetics of doxorubicin (SLNP-Dox and LNP-Dox) and IC1 (SLNP-IC1 and SLNP-IC1-RGD). [Figure 14] Cytotoxicity evaluation of IC1 in EMT-6 cells in vitro. [Figure 15] Cytotoxicity evaluation of IC1 in 4T-1 cells in vitro. [Figure 16] Tumor inhibition of SLNP-IC1 at multiple doses compared to Doxil (LNP-Dox) using EMT-6 cells in vivo. [Figure 17] In-vivo validation of doxorubicin prodrug efficacy in the EMT-6 tumor model. [Figure 18] In-vivo validation of doxorubicin prodrug efficacy in the EMT-6 breast cancer tumor model. [Figure 19] In-vivo validation of multiple doses of doxorubicin prodrug efficacy alone and / or in combination with DSR-6434-stearic acid in solid lipid nanoparticles ("SLNPs") in the EMT-6 tumor model. [Figure 20] Maximum tolerated dose ("MTD") of doxorubicin prodrug alone and in combination with DSR-6434-stearic acid in solid lipid nanoparticles ("SLNPs") in a Balb / c mouse model. [Figure 21] In-vivo validation of doxorubicin prodrug efficacy in the B16F10 melanoma tumor model. [Figure 22] In-vivo validation of doxorubicin prodrug efficacy in the MPC11 multiple myeloma tumor model. [Figure 23] In-vivo validation of doxorubicin prodrug efficacy in the Neuro2A neuroblastoma tumor model. [Figure 24] In-vivo validation of doxorubicin prodrug efficacy in the CT26 colon tumor model. [Diagram 25]In-vivo validation of doxorubicin prodrug efficacy in the MC38 colon tumor model. [Figure 26] In-vivo validation of doxorubicin prodrug efficacy in the Renca kidney tumor model. [Figure 27] In-vivo validation of doxorubicin prodrug efficacy in the H22 liver tumor model. [Figure 28] In-vivo validation of doxorubicin prodrug efficacy in the Hepa1-6 liver tumor model. [Figure 29] In-vivo validation of doxorubicin prodrug efficacy in the LLC1 lung tumor model. [Diagram 30] In-vivo validation of doxorubicin prodrug efficacy in the KLN205 lung tumor model. [Diagram 31] In-vivo validation of doxorubicin prodrug efficacy in the B16BL6 melanoma tumor model. [Diagram 32] In-vivo validation of doxorubicin prodrug efficacy in the Pan-02.03 pancreatic tumor model. [Diagram 33] In-vivo validation of doxorubicin prodrug efficacy in the RM-1 prostate tumor model. [Diagram 34] In-vivo validation of doxorubicin prodrug efficacy in the MBT2 bladder tumor model. [Diagram 35] In-vivo validation of doxorubicin prodrug efficacy in the clonal M-3 melanoma tumor model. [Diagram 36] In-vivo validation of doxorubicin prodrug efficacy in the 4T1 breast orthotopic tumor model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] Detailed Description of the Invention Section Overview I.) Definition II.) Prodrugs III.) Chemical compounds IV.) Lipids V.) Consolidated Units (“LU”) VI.) Nanocarriers VII.) Liposomes VIII.) Pharmaceutical Formulations IX.) Combination Therapies X.) Methods for delivering liposomes containing prodrugs to cells XI.) Methods of Treating Cancer and Other Immunological Disorders XII.) Kits / Articles of Manufacture

[0029] I.) Definition: Unless otherwise defined, all technical terms, designations, and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those skilled in the art to which the present invention pertains, unless otherwise clearly indicated by context. In some cases, terms having commonly understood meanings are defined herein for clarity and / or ready reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference from what is commonly understood in the art.

[0030] When trade names are used herein, a reference to the trade name also refers to product formulations, generic drugs, and active pharmaceutical ingredients of the trade name products, unless otherwise indicated by context.

[0031] As used herein, the term "about" when referring to a value or amount of size (i.e., diameter), weight, concentration, or percentage is meant to encompass variations from the specified amount of ±20% or ±10% in one example, ±5% in another example, ±1% in another example, and ±0.1% in yet another example, such variations being as appropriate for performing the disclosed methods.

[0032] As used herein, the term "and / or," when used in the context of a list of entities, refers to the entities present either alone or in combination. Thus, for example, the phrase "A, B, C, and / or D" includes not only A, B, C, and D individually, but also any and all combinations and subcombinations of A, B, C, and D.

[0033] Numerical ranges recited herein by endpoints include all numbers and fractions subsumed within that range (e.g., 1 to 5 includes, but is not limited to, 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5).

[0034] As used herein, the phrase "consisting essentially of" limits the scope of the claim to the specified materials or steps and those, in addition, that do not materially affect the basic and novel characteristics of the claimed subject matter.

[0035] The terms "advanced cancer," "locally advanced cancer," "advanced disease," and "locally advanced disease" refer to cancer that has spread through the relevant tissue capsule, and are meant to include stage C disease under the American Urological Association (AUA) system, stages C1-C2 disease under the Whitmore-Jewett system, and stages T3-T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, who have a substantially less favorable prognosis compared to patients with clinically localized (organ-confined) cancer.

[0036] As used herein, the term "alkyl" refers to any alkyl group having a C1 to C 20"Branched" may refer to a hydrocarbon chain that is saturated or at least partially and in some cases unsaturated (i.e., alkenyl and alkynyl) that is (including endpoints), linear (i.e., "straight chain"), branched, or cyclic, including, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, octyl, ethenyl, propenyl, butenyl, pentenyl, hexenyl, octenyl, butadienyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, and arenyl groups. "Branched" refers to an alkyl group in which a lower alkyl group, such as methyl, ethyl, or propyl, is attached to a linear alkyl chain. "Lower alkyl" refers to an alkyl group having from 1 to about 8 carbon atoms (i.e., C1-C8 alkyl), for example, 1, 2, 3, 4, 5, 6, 7, or 8 carbon atoms. "Higher alkyl" refers to an alkyl group having from about 10 to about 20 carbon atoms, e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. In certain embodiments, "alkyl" refers, in particular, to C1-C8 straight chain alkyls. In other embodiments, "alkyl" refers, in particular, to C1-C8 straight chain alkyls. 1~8 Refers to branched chain alkyl.

[0037] An alkyl group can be optionally substituted with one or more alkyl group substituents, which can be the same or different ("substituted alkyl"). The term "alkyl group substituent" includes, but is not limited to, alkyl, substituted alkyl, halo, arylamino, acyl, hydroxyl, aryloxyl, alkoxyl, alkylthio, arylthio, aralkyloxyl, aralkylthio, carboxyl, alkoxycarbonyl, oxo, and cycloalkyl. In some embodiments, one or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms can be optionally inserted along the alkyl chain, where the nitrogen substituent is hydrogen, lower alkyl (also referred to herein as "alkylaminoalkyl"), or aryl.

[0038] Thus, as used herein, the term "substituted alkyl" includes alkyl groups, as defined herein, in which one or more atoms or functional groups of the alkyl group have been replaced with another atom or functional group, including, for example, alkyl, substituted alkyl, halogen, aryl, substituted aryl, alkoxyl, hydroxyl, nitro, amino, alkylamino, dialkylamino, sulfate, and mercapto.

[0039] The term "aryl" is used herein to refer to an aromatic substituent, which may be a single aromatic ring or multiple aromatic rings fused together, covalently linked, or linked to a common group, such as, but not limited to, a methylene or ethylene moiety. The common linking group may also be a carbonyl, as in benzophenone, or an oxygen, as in diphenylether, or a nitrogen, as in diphenylamine. The term "aryl" specifically encompasses heterocyclic aromatic compounds. Aromatic rings may include, among others, phenyl, naphthyl, biphenyl, diphenylether, diphenylamine, and benzophenone. In certain embodiments, the term "aryl" refers to an aromatic ring containing about 5 to about 10 carbon atoms, e.g., 5, 6, 7, 8, 9, or 10 carbon atoms, including 5- and 6-membered aromatic and heteroaromatic rings. Aryl groups can be optionally substituted with one or more aryl group substituents which can be the same or different ("substituted aryls"), where the "aryl group substituents" include alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, and -NR'R", where R' and R" can each independently be hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, and aralkyl. Specific examples of aryl groups include, but are not limited to, cyclopentadienyl, phenyl, furan, thiophene, pyrrole, pyran, pyridine, imidazole, benzimidazole, isothiazole, isoxazole, pyrazole, pyrazine, triazine, pyrimidine, quinoline, isoquinoline, indole, carbazole, and the like.

[0040] "Heteroaryl," as used herein, refers to an aryl group that includes one or more non-carbon atoms (e.g., O, N, S, Se, etc.) in the backbone of the ring structure. Nitrogen-containing heteroaryl moieties include, but are not limited to, pyridine, imidazole, benzimidazole, pyrazole, pyrazine, triazine, pyrimidine, etc.

[0041] The terms "anti-cancer drug," "chemotherapeutic drug," and "anti-cancer prodrug" refer to drugs (i.e., chemical compounds) or prodrugs that are known or suspected to treat cancer (i.e., kill cancer cells, prevent the growth of cancer cells, or treat a symptom associated with cancer). In some embodiments, the term "chemotherapeutic drug," as used herein, refers to a non-PS molecule that is used to treat cancer and / or has cytotoxic capabilities. More classical or conventional chemotherapeutic agents can be described by their mechanism of action or class of chemical compound, and can include, but are not limited to, alkylating agents (e.g., melphalan), anthracyclines (e.g., doxorubicin), cytoskeletal disrupting agents (e.g., paclitaxel), epothilones, histone deacetylase inhibitors (e.g., vorinostat), inhibitors of topoisomerase I or II (e.g., irinotecan or etoposide), kinase inhibitors (e.g., bortezomib), nucleotide analogs or precursors thereof (e.g., methotrexate), peptide antibiotics (e.g., bleomycin), platinum-based agents (e.g., cisplatin or oxaliplatin), retinoids (e.g., tretinoin), and vinca alkaloids (e.g., vinblastine).

[0042] "Aralkyl" refers to an -alkyl-aryl group, in which the alkyl and / or aryl portions are optionally substituted.

[0043] "Alkylene" refers to a straight or branched chain divalent aliphatic hydrocarbon group having 1 to about 20 carbon atoms, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 carbon atoms. The alkylene group may be straight, branched, or cyclic. The alkylene group may also be optionally unsaturated and / or substituted with one or more "alkyl group substituents." Optionally, one or more oxygen, sulfur, or substituted or unsubstituted nitrogen atoms may be inserted along the alkylene group (also referred to herein as "alkylaminoalkyi"), the nitrogen substituent being alkyl, as previously described. Exemplary alkylene groups include methylene (-CH-), ethylene (-CH-CH-), propylene (-(CH)-), cyclohexylene (-CH 10 -), -CH=CH-CH=CH-, -CH=CH-CH2-, -(CH2) q Examples of alkylene groups include -N(R)-(CH2),- (wherein each q is an integer from 0 to about 20, e.g., 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, and R is hydrogen or lower alkyl), methylenedioxyl (-O-CH2-O-), and ethylenedioxyl (-O-(CH2)2-O-). The alkylene group can have from about 2 to about 3 carbon atoms and can further have from 6 to 20 carbons.

[0044] The term "arylene" refers to a divalent aromatic group, such as a divalent phenyl or naphthyl group. The arylene group may be optionally substituted with one or more aryl group substituents and / or may contain one or more heteroatoms.

[0045] The term "amino" refers to the group -N(R)2, where each R is independently H, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, or substituted aralkyl. The terms "aminoalkyl" and "alkylamino" can refer to the group -N(R)2, where each R is H, alkyl, or substituted alkyl, and at least one R is alkyl or substituted alkyl. "Arylamine" and "aminoaryl" refer to the group -N(R)2, where each R is H, aryl, or substituted aryl, and at least one R is aryl or substituted aryl, such as aniline (i.e., -NHC6H5).

[0046] "Bulk drug" (also known as drug substance) means an active pharmaceutical ingredient or drug product that has not been filled into a final container for distribution. Final formulated bulk drug generally refers to a drug product that has been formulated and stored or held prior to filling. A drug substance may be stored or held as a "bulk drug" or "concentrated bulk drug" prior to formulation into a drug product.

[0047] The terms "carboxylate" and "carboxylic acid" refer to the radical -C(=O)O - and -C(=O)OH. The term "carboxyl" can also refer to the group -C(=O)OH.

[0048] The terms "conjugate" and "conjugated" as used herein may refer to the binding (e.g., covalent bonding) of two or more components (e.g., chemical compounds, polymers, biomolecules, particles, etc.) to each other. In some embodiments, a conjugate may include monovalent moieties derived from two different chemical compounds covalently linked via a bivalent linker moiety (e.g., an optionally substituted alkylene or arylene). In some embodiments, the linker may include one or more biodegradable bonds such that one or more bonds in the linker may be broken when the prodrug is exposed to certain physiological environments or enzymes (e.g., esterases).

[0049] The term "compound" includes the chemical compound (e.g., prodrug) per se, as well as the following, whether or not expressly mentioned and unless the context makes it clear that the following are excluded: amorphous and crystalline forms of the compound, including polymorphic forms, which may be part of a mixture or in an isolated state; free acid and free base forms of the compound, which are typically those forms shown in the structures provided herein; isomers of the compound, which refers to optical isomers and tautomers, where optical isomers include enantiomers and diastereomers, chiral isomers and non-chiral isomers, and optical isomers include isolated optical isomers as well as mixtures of optical isomers, including racemic and non-racemic mixtures, and the isomers may be in isolated form or in a mixture with one or more other isomers; isomers of the compound, which refers to optical isomers and tautomers, where optical isomers include enantiomers and diastereomers, chiral isomers and non-chiral isomers, and optical isomers include isolated optical isomers as well as mixtures of optical isomers, including racemic mixtures and non-racemic mixtures, and the isomers may be in isolated form or in a mixture with one or more other isomers; isomers of the compound, which refers to the isomers of the compound, which may be in isolated form or in a mixture with one or more other isomers; multimeric forms of the compounds, including dimeric, trimeric, and the like forms; salts of the compounds, preferably pharma- ceutically acceptable salts, including acid addition salts and base addition salts, including salts with organic and inorganic counterions, and zwitterionic forms, where when the compound is associated with two or more counterions, the two or more counterions may be the same or different; and solvates of the compounds, including organic solvates and inorganic solvates, such as hemisolvates, monosolvates, disolvates, and the like, where the inorganic solvates include hydrates, where when the compound is associated with two or more solvent molecules, the two or more solvent molecules may be the same or different. In some cases, reference made herein to the compounds of the invention includes an explicit reference to one or more of the above-mentioned forms, e.g., salts and / or solvates; however, this reference is made for emphasis only and is not to be construed as excluding any other of the above-mentioned forms identified above.

[0050] "Drug product" generally refers to a final formulation containing an active pharmaceutical ingredient (i.e., a liposome containing an ICD-derived prodrug) in association with, but not necessarily, an inactive ingredient. The term also includes final dosage forms that do not contain an active ingredient but are intended to be used as a placebo.

[0051] The term "disulfide" may refer to a -SS- group.

[0052] The term "empty vesicles" refers to unloaded lipid vesicles by themselves.

[0053] The term "ester", as used herein, means a chemical compound derived from an acid (organic or inorganic) in which at least one -OH hydroxyl group is replaced by an -O-alkyl (alkoxy) or -O-aryl (aryloxy) group.

[0054] The term "esterase," as used herein, is a hydrolase enzyme that splits an ester into an acid and an alcohol.

[0055] "Excipient" refers to an inert substance used as a carrier of an active ingredient in a drug, such as a vaccine. Excipients may also be used to bulk up formulations with highly potent active ingredients to allow for convenient and accurate dosing. Examples of excipients include, but are not limited to, anti-adhesives, binders, coatings, disintegrants, fillers, diluents, flavors, colorants, lubricants, and preservatives.

[0056] The terms "halo," "halide," or "halogen," as used herein, refer to fluoro, chloro, bromo, and iodo groups.

[0057] The term "hydrazone" or "hydrazones" refers to a class of organic compounds having the structure R1R2C=NNH3.

[0058] The term "hydrazone linker" refers to an acid-cleavable linker that is specifically designed to remain stable at the neutral pH of the blood circulation but undergo hydrolysis to release the linked compound in the acidic environment of the cellular compartment.

[0059] The terms "hydroxyl" and "hydroxy" refer to the --OH group.

[0060] The terms "inhibit" or "inhibition of," as used herein, mean to reduce by a measurable amount or to prevent completely.

[0061] The terms "individual" or "patient" when used in the context of this disclosure may be used interchangeably.

[0062] As used herein, the term "ligand" generally refers to one species, e.g., a molecule or ion, that interacts with, e.g., binds to, another species in some manner. See Martell, AE, and Hancock, RP, Metal Complexes in Aqueous Solutions, Plenum: New York (1996), which is incorporated herein by reference in its entirety.

[0063] The term "lipid" as used herein refers to a class of naturally occurring (organic) compounds that are insoluble in polar solvents.In the context of this disclosure, lipid refers to conventional lipids, phospholipids, cholesterol, PEG and chemically functionalized lipids for binding ligands, etc.

[0064] The term "lipid bilayer" or "LB" refers to any bilayer of amphiphilic lipid molecules oriented with their hydrocarbon tails pointing inward to form a continuous non-polar phase.

[0065] The terms "liposome" or "lipid vesicle" or "vesicle" are used interchangeably to refer to an aqueous compartment enclosed by a lipid bilayer as conventionally defined (see Stryer (1981) Biochemistry, 2d Edition, WH Freeman & Co., p. 213).

[0066] The term "mammal" refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses, and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.

[0067] The term "mercapto" or "thiol" refers to a -SH group.

[0068] The terms "metastatic cancer" and "metastatic disease" refer to cancer that has spread to regional lymph nodes or distant sites, and are meant to include stage D disease under the AUA system and stage TxNxM+ under the TNM system.

[0069] The terms "nanocarrier," "nanoparticle," and "nanoparticle drug carrier" are used interchangeably and refer to nanostructures having a water-soluble, solid, or polymeric inner core. In certain embodiments, nanocarriers comprise a lipid bilayer that envelops (or surrounds or encapsulates) a porous particle core. In certain embodiments, nanocarriers are liposomes, lipid nanoparticles ("LNPs"), or solid lipid nanoparticles ("SLNPs").

[0070] The terms "nanoscale particle," "nanomaterial," "nanocarrier," and "nanoparticle" refer to a structure having at least one region with a dimension (e.g., length, width, diameter, etc.) of less than about 1,000 nm. In some embodiments, the dimension is smaller (e.g., less than about 500 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 125 nm, less than about 100 nm, less than about 80 nm, less than about 70 nm, less than about 60 nm, less than about 50 nm, less than about 40 nm, less than about 30 nm, or even less than about 20 nm). In some embodiments, the dimensions are from about 20 nm to about 250 nm (e.g., about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, or 250 nm).

[0071] The term "nanovesicle" refers to a "lipid vesicle" (or a population of vesicles having such an average diameter) having a diameter ranging from about 20 nm, or from about 30 nm, or from about 40 nm, or from about 50 nm, up to about 500 nm, or up to about 400 nm, or up to about 300 nm, or up to about 200 nm, or up to about 150 nm, or up to about 100 nm, or up to about 80 nm. In certain embodiments, the nanovesicle has a diameter ranging from about 40 nm to about 80 nm, or from about 50 nm to about 70 nm.

[0072] "Pharmaceutically acceptable" refers to a non-toxic, inert, and / or composition that is physiologically compatible with humans or other mammals.

[0073] "Pharmaceutical formulation" refers to the process of combining different chemicals into pure drug substances to produce a final drug product.

[0074] The term "phosphonate" refers to the group -P(=O)(OR)2, where each R can be independently H, alkyl, aralkyl, aryl, or negative charge (i.e., effectively, there is no R group attached to the oxygen atom and there is an unshared electron pair on the oxygen atom). Thus, in other words, each R can be present or absent, and when present, is selected from H, alkyl, aralkyl, or aryl.

[0075] The term "phosphate" refers to the group -OP(=O)(OR')2, where R' is H or a negative charge.

[0076] The term "prodrug" refers to a pharmaceutical agent or compound that is metabolized into a pharmacologically active drug after administration. For purposes of this disclosure, the prodrugs of the present invention contain three components: (i) a drug moiety, (ii) a lipid moiety, and (iii) a linking unit ("LU").

[0077] The term "ICD prodrug" refers to a prodrug of the present invention where the drug moiety comprises an ICD inducer.

[0078] The term "pyrolipid" refers to a conjugate of a lipid with a porphyrin, a porphyrin derivative, or a porphyrin analog. In some embodiments, a pyrolipid may include a lipid conjugate in which a porphyrin or a derivative or analog thereof is covalently attached to a lipid side chain. See, for example, U.S. Patent Application Publication No. 2014 / 0127763.

[0079] As used herein, the terms "specific," "specifically binds," and "binds specifically" refer to the selective binding of the nanocarriers of the present invention to a target of interest, inducing ICD.

[0080] The term "supported lipid bilayer" refers to a lipid bilayer that encapsulates a porous particle core. This definition described in the present disclosure is given because the lipid bilayer is located on the surface and is supported by the porous particle core. In certain embodiments, the lipid bilayer can have a thickness ranging from about 6 nm to about 7 nm, which includes a hydrated hydrophilic head base layer (about 0.9 nm each) in addition to a 3-4 nm thick hydrophobic core, plus two partially hydrated regions of about 0.3 nm each. In various embodiments, the lipid bilayer surrounding the liposome comprises a continuous or substantially continuous bilayer that effectively encapsulates and seals the ICD-inducing agent.

[0081] The term "thioalkyl" may refer to the group -SR, where R is selected from H, alkyl, substituted alkyl, aralkyl, substituted aralkyl, aryl, and substituted aryl. Similarly, the terms "thioaralkyl" and "thioaryl" refer to the group -SR, where R is aralkyl and aryl, respectively.

[0082] As used herein, "to treat" or "therapeutic" and grammatically related terms refer to any improvement in any outcome of a disease, e.g., increased survival, reduced pathology, and / or reduced side effects that are a by-product of alternative therapeutic modalities; complete eradication of the disease, although preferred, is not a requirement for the treatment effect, as is readily understood in the art.

[0083] The term "therapeutically effective amount" refers to that amount of an active prodrug, nanoencapsulated prodrug, or pharmaceutical agent that elicits a biological or medical response in a tissue, system, animal, individual, or human.

[0084] The term "unsupported lipid bilayer" means a lipid bilayer that is not coated in a lipid vesicle or liposome.

[0085] II.) Prodrugs As shown in this disclosure, and for the purposes of the present invention, suitable prodrugs are formed by conjugating a drug moiety of the present invention (see the section entitled Drug Moiety) to a lipid moiety of the present invention (see the section entitled Lipid) via a LU of the present disclosure (see the section entitled Linking Unit). For the purposes of the present disclosure, the formation of an ICD prodrug may utilize several strategies. (See, for example, Figures 2, 3, and 4).

[0086] Thus, in some embodiments, the prodrug is a drug-lipid moiety that comprises an ICD-inducing agent of the present disclosure.

[0087] In one embodiment, the prodrug is a drug-lipid moiety that includes an ICD-inducing agent as described in FIG.

[0088] In one embodiment, the prodrug is a drug-lipid moiety that includes an ICD-inducing agent as described in FIG.

[0089] In one embodiment, the prodrug is a drug-lipid moiety that includes an ICD-inducing agent as described in FIG.

[0090] In a further embodiment, the ICD prodrug is a drug-lipid moiety that comprises a lipid of the present disclosure.

[0091] In a further embodiment, the ICD prodrug is a drug-lipid moiety in which the lipid is CHEMS.

[0092] In a further embodiment, the ICD prodrug is a drug-lipid moiety where the lipid is stearic acid.

[0093] In a further embodiment, the ICD prodrug is a drug-lipid moiety comprising a LU of the present disclosure.

[0094] In a further embodiment, the ICD prodrug is a drug-lipid moiety where LU is a hydromethylcarbamate linker.

[0095] In a further embodiment, the ICD prodrug is a drug-lipid moiety in which LU is a hydrazone linker.

[0096] In a further embodiment, the ICD prodrug is a drug-lipid moiety in which LU is a hydrazone.

[0097] In a further embodiment, the prodrug is a drug-lipid moiety that comprises an ICD inducer of the present invention, where the ICD inducer comprises a chemical composition designated IC1.

[0098] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and has the following chemical structure: [ka] has.

[0099] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and has the following chemical formula: [ka] Further included is a lipid of the present disclosure having the formula:

[0100] In a further embodiment, the prodrug is a drug-lipid moiety that comprises an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises CHEMS.

[0101] In a further embodiment, the prodrug is a drug-lipid moiety that comprises an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises stearic acid.

[0102] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises CHEMS, and LU is a hydromethylcarbamate linker.

[0103] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises stearic acid, and LU is a hydromethylcarbamate linker.

[0104] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises CHEMS, and LU is a hydrazone linker.

[0105] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and further comprises stearic acid, and LU is a hydrazone linker.

[0106] In a further embodiment, the prodrug is a drug-lipid moiety comprising an ICD inducer of the invention, where the ICD inducer comprises IC1 and has the following structure: [ka] The stearic acid further comprises

[0107] In an additional embodiment of the present disclosure, the subject matter provides an ICD inducer prodrug comprising a therapeutic parent drug conjugated to lipid. In some embodiments, the prodrug comprises (a) a monovalent drug moiety, (b) a monovalent lipid moiety, and (c) a bivalent linker moiety comprising a linking unit that degrades in vivo, e.g., a disulfide bond, where the monovalent drug moiety and the monovalent lipid moiety are linked (e.g., covalently linked) via a linker. The monovalent drug moiety and the monovalent lipid moiety may be monovalent derivatives of chemical compounds and lipids, respectively. For example, the monovalent derivative may be a deprotonated derivative of a chemical compound or lipid comprising a hydroxyl, thiol, amino, or carboxylic acid group.

[0108] In a further embodiment of the present disclosure, the subject matter provides an ICD inducer prodrug comprising a therapeutic parent drug conjugated to lipid. In some embodiments, the prodrug comprises (a) a bivalent drug moiety, (b) a bivalent lipid moiety, and (c) a bivalent linker moiety comprising a linkage that degrades in vivo, where the bivalent drug moiety and the bivalent lipid moiety are linked (e.g., covalently linked) via a linker. The bivalent drug moiety and the bivalent lipid moiety may be bivalent derivatives of chemical compounds and lipids, respectively. For example, the bivalent derivatives may be deprotonated derivatives of chemical compounds or lipids that comprise hydroxyl, thiol, amino, or carboxylic acid groups.

[0109] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0110] III.) Drug Moiety Another aspect of the present invention provides novel ICD prodrug compounds, including an ICD inducer having the following formula, designated IC1:

[0111] Those skilled in the art will understand that compounds are useful as ICD inducers in that they induce or mediate immunogenic cell death by various means known in the art. By way of brief background, ICD is a form of apoptosis characterized by the release of certain molecules that are a class of the danger-associated molecular pattern (DAMP) family. DAMPs are intracellular factors that are not typically found in living cells and that acquire immunostimulatory properties when exposed or secreted by dying cells. DAMPs can be divided into three main subclasses depending on their stage and location of localization / release. One subclass of DAMPs appears on the cell surface (e.g., CRT, HSP 70, HSP 90). Another subclass of DAMPs appears outside the cell (e.g., HMGB1, uric acid, and pro-inflammatory cytokines). The last subclass of DAMPs appears as late degradative factors (e.g., ATP, DNA, and RNA).

[0112] Generally, DAMPs are sensitized by pattern recognition receptors, including toll-like receptors (TLRs), NOD-like receptors (NLRs), and retinoic acid-inducible gene I-like receptors (RIG-I-like receptors (RLRs)). Major DAMPs include CRT, HMGB1, ATP, HSP 70 and 90, as well as type 1 interferon and ANXA1. These molecules recruit and trigger immune cells by sensitizing their receptors, which leads to phagocytosis and activation of T lymphocytes to eradicate tumor cells. See KROEMER, et. al., Annu. Rev. Immunol. 2013, 31, pp. 51-72. The ability of DAMPs to be produced during ICD depends on endoplasmic reticulum (ER) stress, which occurs simultaneously or is activated by reactive oxygen species (ROS). See ASADZADEH, et. al., Cancers 2020, 12, 1047 (pp. 1-38).

[0113] There are several ICD-inducing compounds known in the art, including, but not limited to, daunorubicin, docetaxel, doxorubicin, mitoxantrone, oxaliplatin, paclitaxel, digitoxin, dogotoxin, and sputacidin.See KEPP, et. al., Oncotarget (July 2014): 5(14): pp. 5190-5191.

[0114] Based on the above, the present disclosure describes a class of ICD inducers.

[0115] In one embodiment, the drug moiety of the present disclosure has the following chemical structure: [ka] The compound (designated IC1) has the formula:

[0116] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0117] IV.) Lipids Generally speaking, and for the purposes of this disclosure, the term "lipid" is used in its broadest sense and includes several subcategories of lipids, including but not limited to phospholipids / fatty acids. As will be understood by those skilled in the art, phospholipids represent a class of lipids that are major components of all cell membranes. Phospholipids can form lipid bilayers due to their amphipathic characteristics. The structure of a phospholipid molecule generally consists of two hydrophobic fatty acid "tails" and a hydrophilic "head" consisting of a phosphate group that may be modified with a simple organic molecule, e.g., choline, ethanolamine, or serine. These two components are usually linked together by a glycerol molecule. A representative list of phospholipids / fatty acids of the present invention is set forth in Table III.

[0118] As a brief background, at the most fundamental level, the properties of liposomes depend on the intricate physicochemical interactions between the various lipid species in their composition. Individual lipids can be combined to form numerous superstructures, including bilayers, and the properties of the bilayers can be tailored to modulate drug release and membrane stability. In a simplified bilayer model, the length of the acyl chains determines the thickness and phase transition temperature (Tm) of the bilayer, the saturation of the acyl chains controls the fluidity of the bilayer, and the head group interactions affect the inter- and intra-lipid forces. The behavior of liposomes can be tuned by incorporating synthetic lipids, such as lipid prodrugs, fusogenic lipids, and functionalizable lipids, into the bilayer. See KOHLI, et. al., J. Control Release, 0: pp. 274-287 (Sept. 28, 2014).

[0119] In one embodiment of the disclosure, the ICD prodrug comprises a monovalent lipid moiety.

[0120] In one embodiment, the ICD prodrug comprises a divalent lipid moiety.

[0121] In one embodiment, the lipid has the following chemical structure: [ka] Cholesterol having the formula:

[0122] In one embodiment, the lipid has the following chemical structure: [ka] The DPPG has the formula:

[0123] In one embodiment, the lipid has the following chemical structure: [ka] The compound includes DMPG having the formula:

[0124] In one embodiment, the lipid has the following chemical structure: [ka] The Lyso PC having the formula:

[0125] In one embodiment, the lipid has the following chemical structure: [ka] The (Δ9-Cis)PG has the formula:

[0126] In one embodiment, the lipid has the following chemical structure: [ka] Soy Lyso PC having the formula:

[0127] In one embodiment, the lipid has the following chemical structure: [ka] The PG has the formula:

[0128] In one embodiment, the lipid has the following chemical structure: [ka] C16 PEG2000 ceramide (Ceramde) having the formula:

[0129] In one embodiment, the lipid has the following chemical structure: [ka] and cholesterol hemisuccinate ("CHEMS"), having the formula:

[0130] For reference, a complete list of the lipid formulas and abbreviations disclosed herein is set forth in Table I.

[0131] In additional embodiments, the lipid comprises a phospholipid / fatty acid disclosed herein and set forth in Table III.

[0132] In a further embodiment, the lipid comprises stearic acid.

[0133] In addition, the ICD prodrugs and / or liposomes of the present disclosure may include one or more helper lipids, also referred to herein as "helper lipid components". The helper lipid components are preferably selected from the group including phospholipids and steroids. The phospholipids are preferably diesters and monoesters of phosphoric acid. Preferred members of the phospholipids are phosphoglycerides and sphingolipids. Steroids, as used herein, are naturally occurring and synthetic compounds based on partially hydrogenated cyclopenta[a]phenanthrene. Preferably, the steroids include 21-30 C atoms. A particularly preferred steroid is cholesterol.

[0134] Without wishing to be bound by any theory, it is noted that due to the specific molar percentage of helper lipids contained in the lipid composition according to the invention, which may be either PEG-free helper lipids or in particular PEG-containing helper lipids, more particularly when the content of any of this type of helper lipid is comprised within the concentration ranges specified herein, surprising effects may be achieved.

[0135] In a further aspect of the present invention, the lipid composition, preferably present as a lipoplex or liposome, preferably exhibits a neutral or overall anionic charge. The anionic lipid is preferably any neutral or anionic lipid described herein. The lipid composition, in a preferred embodiment, comprises any helper lipid or combination of helper lipids, and any ICD inducer described herein (e.g., IC1). In a further embodiment, the composition according to the present invention, comprising nucleic acid, forms a lipoplex. In a preferred embodiment, the term lipoplex, as used herein, refers to a composition composed of neutral or anionic lipids of the present invention, neutral helper lipids, and an ICD inducer. For references to the use of helper lipids in the art, see, e.g., U.S. Patent Application Publication No. 2011 / 0178164, OJEDA, et. al., Int. J. of Pharmaceutics (March 2016), DABKOWSKA, et. al., JR Soc. Interface 9, pp. 548-561 (2012), and MOCHIZUKI, et. al., Biochimica et. Biophysica Acta, 1828, pp. 412-418 (2013).

[0136] In a preferred embodiment, the helper lipids of the present invention comprise the helper lipids set forth in Table II.

[0137] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is CHEMS and the drug moiety is IC1.

[0138] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is CHEMS and the drug moiety is any of IC1's, and further comprises LU, where LU is a hydromethylcarbamate linker.

[0139] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is CHEMS and the drug moiety is any of IC1, and further comprises LU, where LU is a hydrazone linker.

[0140] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is a CHEMS, the drug moiety is any of IC1, and further comprises LU, where LU is a hydromethylcarbamate linker, and further comprises a helper lipid moiety, where the helper lipid moiety comprises a helper lipid of Table II.

[0141] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is CHEMS, the drug moiety is any of IC1, and further comprises LU, where LU is a hydrazone linker, and further comprises a helper lipid moiety, where the helper lipid moiety comprises a helper lipid of Table II.

[0142] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is a CHEMS and the drug moiety is any of IC1, and CHEMS is monovalent.

[0143] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the drug moiety is any of the IC1s.

[0144] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid, the drug moiety is any of IC1, and the stearic acid is monovalent.

[0145] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid, the drug moiety is any of IC1, and further comprises LU, where LU is a hydromethylcarbamate linker.

[0146] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid, the drug moiety is any of IC1, and further comprises LU, where LU is a hydrazone linker.

[0147] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the drug moiety is any of IC1, and further comprises LU, where LU is a hydrazone.

[0148] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the chemical composition is any of IC1, and further comprises LU, where LU is a hydromethylcarbamate linker, and further comprises a helper lipid moiety, where the helper lipid moiety comprises a helper lipid of Table II.

[0149] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the chemical composition is any of IC1, and further comprises LU, where LU is a hydrazone linker, and further comprises a helper lipid moiety, where the helper lipid moiety comprises a helper lipid of Table II.

[0150] In one embodiment, an ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the drug moiety is any of the IC1s.

[0151] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid, the drug moiety is any of the IC1s, and the AR prodrug is synthesized according to Example 1 described herein.

[0152] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid, the drug moiety is any of the IC1s, and the AR prodrug is synthesized according to FIG. 1 described herein.

[0153] In one embodiment, the ICD prodrug comprises a lipid of the invention, where the lipid is stearic acid and the drug moiety has the following chemical structure: [ka] The IC1 may be any of the ICs having the following characteristics:

[0154] In one embodiment, a class of hydrazone lipids is disclosed herein.As previously taught above, typical hydrazone lipids are listed in Table III.In addition, the hydrazone lipids of the present disclosure have the following chemical formula: [ka] is described in In the formula, n=8 to 30.

[0155] In a further embodiment, the hydrazone lipid of the present disclosure has the following formula: [ka] is described in In the formula, x=3 to 16; In the formula, y=3 to 16.

[0156] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0157] V.) Consolidated Units (“LU”) In some embodiments, the presently disclosed subject matter provides prodrugs that include drug-lipid conjugates that include biodegradable linkages, such as esters, thioesters, and other linkers known in the art.

[0158] Exemplary embodiments of ester chemistry are described herein: [ka]

[0159] In some embodiments, the prodrug is a drug-lipid conjugate, and the drug-lipid conjugate is cleaved by an esterase.

[0160] In one embodiment, the prodrugs of the present invention comprise LU via a secondary amine, amide, or aniline using the following scheme: [ka] An exemplary synthesis is as follows: [ka] Cleavage of prodrug structures containing secondary amines, amides, or anilines can be achieved by esterase hydrolysis of the secondary amine, amide, or aniline prodrug under the following exemplary synthesis: [ka] During the ceremony, R1-NH-R2 can be any molecule that has a secondary amine, amide, or aniline.

[0161] In one embodiment, the secondary amide nitrogen of the IC1 drug moiety is conjugated to CHEMS via a hydromethylcarbamate linker.

[0162] In one embodiment, the secondary amide nitrogen of the IC1 drug moiety is conjugated to stearic acid via a hydromethylcarbamate linker.

[0163] In further embodiments, the presently disclosed subject matter provides prodrugs that involve hydrazone hydrolysis under aqueous acidic conditions to release the drug as a free ketone and lipid-hydrazine derivative, utilizing the following exemplary synthesis: [ka]

[0164] In a further preferred embodiment, the IC1 prodrugs of the present disclosure utilize hydrazone hydrolysis under aqueous acidic conditions to release the IC1 drug moiety (see the section entitled "Drug Moiety"), releasing IC1 and a lipid-hydrazine derivative under the following exemplary synthesis. [ka]

[0165] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0166] VI.) Nanocarriers Generally speaking, and for purposes of this disclosure, nanocarriers are within the scope of the present invention. Nanocarriers are nanomaterials that are used as transport modules for other substances, such as drugs. Commonly used nanocarriers include micelles, polymers, carbon-based materials, liposomes, and other materials. Due to their small size, nanocarriers can deliver drugs to sites in the body that are otherwise inaccessible. Nanocarriers can include polymer conjugates, polymer nanoparticles, lipid-based carriers, dendrimers, carbon nanotubes, and gold nanoparticles. Lipid-based carriers include both liposomes and micelles. In certain embodiments, the nanocarriers are liposomes, lipid nanoparticles ("LNP"), or solid lipid nanoparticles ("SLNP").

[0167] In addition, nanocarriers are useful in the drug delivery process because they can deliver drugs to site-specific targets, allowing drugs to be delivered to certain organs or cells rather than others. Site specificity provides a major therapeutic advantage because it prevents drugs from being delivered to the wrong location. In addition, nanocarriers are promising for use in chemotherapy because they can help reduce the harmful broader toxicity of chemotherapy to healthy, fast-growing cells of the body. Chemotherapeutic drugs can be highly toxic to human cells, so it is important that they are delivered to the tumor without being released to other parts of the body.

[0168] Generally speaking, there are four ways in which nanocarriers can deliver drugs, including passive targeting, active targeting, pH specificity, and temperature specificity.

[0169] Passive targeting refers to the ability of nanocarriers to travel to the tumor vasculature, where they are trapped, and accumulate in the tumor. This accumulation is caused by enhanced permeability and retention. The leaky vasculature of tumors is a network of blood vessels formed in tumors, which contains many pores. These pores not only allow the nanocarriers to enter, but also contain many bends that allow the nanocarriers to become trapped. As more nanocarriers become trapped, the drug accumulates at the tumor site. This accumulation delivers a large dose of drug directly to the tumor site.

[0170] Active targeting involves incorporating targeting modules, such as ligands or antibodies, onto the surface of the nanocarrier that are specific for a particular type of cell in the body. Nanocarriers generally have a high surface area to volume ratio and allow for the incorporation of multiple ligands onto their surface.

[0171] In addition, certain nanocarriers release the drugs they contain only in a certain pH range. pH specificity also allows nanocarriers to deliver drugs directly to tumor sites. This is due to the fact that tumors generally have a pH of approximately 6.8, making them more acidic than normal human cells. Normal tissues have a pH of approximately 7.4. Thus, nanocarriers that release drugs only in a certain pH range can be used to release drugs only in the acidic tumor environment. A highly acidic environment causes the drug to be released due to the acidic environment breaking down the structure of the nanocarrier. Generally, these nanocarriers do not release drugs in neutral or basic environments, effectively targeting the acidic environment of tumors while leaving normal body cells unaffected. This pH sensitivity can also be induced in micellar systems by adding copolymer chains to the micelles, which have been determined to act in a pH-independent manner. See WU, et. al., Biomaterials, 34(4): 1213-1222 (2012). These micelle-polymer complexes also help prevent cancer cells from developing multidrug resistance: the low pH environment triggers a rapid release of the micelle polymer, releasing most of the drug at once, rather than slowly as with other drug treatments.

[0172] In addition, some nanocarriers have also been shown to deliver drugs more effectively at certain temperatures. Because tumor temperatures are generally around 40° C. and higher than the rest of the body, this temperature gradient helps act as a barrier for tumor-specific site delivery. See REZAEI, et. al., Polymer, 53(16): 3485-3497 (2012).

[0173] As disclosed herein, lipid-based nanocarriers, such as liposomes, are within the scope of the present invention. Lipid-based nanoparticles (LBNP or LNP), such as liposomes, solid lipid nanoparticles (SLN), and nanostructured lipid carriers (NLC), can transport hydrophobic and hydrophilic molecules, exhibit minimal or no toxicity, and can increase the time of drug action with extended half-life and controlled drug release. Lipid nanoparticles can include chemical modifications to avoid detection by the immune system (gangliosides or polyethylene glycol (PEG)) or to improve drug solubility. In addition, they can be prepared into pH-sensitive formulations to promote drug release in acidic environments, and can also be associated with small molecules or antibodies that recognize tumor cells and their receptors (e.g., folic acid (FoA)). Nanodrugs can also be used in combination with other therapeutic strategies to improve patient responses. See GARCIA-PINEL, et. al., Nanomaterials 9(639) (2019).

[0174] In various embodiments, the silicasome drug carriers described herein comprise porous silica (or other material) nanoparticles (e.g., silica bodies having a surface and defining a plurality of pores suitable for receiving molecules therein) coated with a lipid bilayer. The fact that the nanoparticles are referred to as silica nanoparticles does not exclude that materials other than silica are also incorporated within the silica nanoparticles. In some embodiments, the silica nanoparticles may be substantially spherical, with a plurality of pore openings through the surface that provide access to the pores. However, in various embodiments, the silica nanoparticles may have shapes other than a substantially spherical shape. Thus, for example, in certain embodiments, the silica nanoparticles may be substantially ovoid, rod-shaped, substantially regular polygonal, irregular polygonal, and the like.

[0175] Generally, silica nanoparticles include a silica body that defines an exterior surface between pore openings as well as sidewalls within the pores. The pores may extend from the silica body to another pore opening, or the pores may extend only partially from the silica body such that they have a base defined by the silica body.

[0176] In some embodiments, the silica body is mesoporous. In other embodiments, the silica body is microporous. As used herein, "mesoporous" means having pores with diameters of about 2 nm to about 50 nm, while "microporous" means having pores with diameters smaller than about 2 nm. Generally, the pores may be of any size, but in typical embodiments, are large enough to contain one or more therapeutic compounds therein. In such embodiments, the pores allow small molecules, e.g., therapeutic compounds, e.g., anti-cancer compounds, to attach or bind to the interior surface of the pores and be released from the silica body when used for therapeutic purposes. In some embodiments, the pores are substantially cylindrical.

[0177] In certain embodiments, the nanoparticles include pores having diameters of about 1 nm to about 10 nm, or pore sizes of about 2 nm to about 8 nm. In certain embodiments, the nanoparticles include pores having diameters of about 1 nm to about 6 nm, or about 2 nm to about 5 nm. Other embodiments include particles having pore sizes less than 2.5 nm.

[0178] In other embodiments, the pore size is between 1.5 and 2.5 nm. Silica nanoparticles having other pore sizes can be prepared, for example, by using different surfactants or swelling agents during preparation of the silica nanoparticles. In various embodiments, the nanoparticles may include particles as large as about 1000 nm (e.g., mean or median diameter (or other characteristic dimension). However, in various embodiments, the nanoparticles are typically less than 500 nm or less than about 300 nm, since particles larger than 300 nm may generally be less effective at entering living cells or vascular fenestrations. In certain embodiments, the nanoparticles range in size from about 40 nm or about 50 nm or about 60 nm, up to about 100 nm or up to about 90 nm or up to about 80 nm or up to about 70 nm. In certain embodiments, the nanoparticles range in size from about 60 nm to about 70 nm. Some embodiments include nanoparticles having an average maximum dimension of about 50 nm to about 1000 nm. Other embodiments include nanoparticles having an average maximum dimension of about 50 nm to about 500 nm. Other embodiments include nanoparticles having an average maximum dimension of about 50 nm to about 200 nm.

[0179] In some embodiments, the average maximum dimension is greater than about 20 nm, greater than about 30 nm, greater than 40 nm, or greater than about 50 nm. Other embodiments include nanoparticles having an average maximum dimension of less than about 500 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 75 nm. As used herein, nanoparticle size refers to the average or median size of the primary particles as measured by transmission electron microscopy (TEM) or similar visualization techniques known in the art. Further examples of mesoporous silica nanoparticles include, but are not limited to, MCM-41, MCM-48, and SBA-15. See KATIYARE, et. al., J. Chromotog. 1122(1-2): 13-20 (2006).

[0180] The method of making porous silica nanoparticles is well known to those skilled in the art. In a particular embodiment, mesoporous silica nanoparticles are synthesized by reacting tetraethyl orthosilicate (TEOS) with a template made of micellar rods. The result is a collection of nano-sized spheres or rods filled with regularly arranged pores. The template can then be removed by washing with a solvent adjusted to an appropriate pH (see, for example, TREWYN et al. (2007) Chem. Eng. J. 137(1): 23-29).

[0181] In certain embodiments, mesoporous particles can also be synthesized using simple sol-gel methods (see, for example, NANDIYANTO, et al. (2009) Microporous and Mesoporous Mat. 120(3): 447-453). In certain embodiments, tetraethyl orthosilicate can also be used with additional polymer monomers as a template. In certain embodiments, 3-mercaptopropyl)trimethoxysilane (MPTMS) is used instead of TEOS.

[0182] In certain embodiments, the mesoporous silica nanoparticles are cores synthesized by a modified version of the sol / gel procedure described by MENG et. al. (2015) ACS Nemo, 9(4): 3540-3557.

[0183] Although the methods described herein are illustrated with respect to porous silica nanoparticles (e.g., mesoporous silica), those skilled in the art will recognize that similar methods can be used with other porous nanoparticles. Numerous other mesoporous materials that can be used in drug delivery nanoparticles are known to those skilled in the art. For example, in certain embodiments, mesoporous carbon nanoparticles can be utilized.

[0184] Mesoporous carbon nanoparticles are well known to those skilled in the art (see, for example, HUANG et. al. (2016) Carbon, 101: 135-142; ZHU et. al. (2014) Asian J. Pharm. Sci., 9(2): 82-91, etc.).

[0185] Similarly, in certain embodiments, mesoporous polymer particles may be utilized. The synthesis of highly ordered mesoporous polymers and carbon frameworks from organic-organic assembly of triblock copolymers with soluble low molecular weight phenolic resin precursors (resols) via an evaporation-induced self-assembly strategy has been reported by MENG, et. al. (2006) Chem. Mat. 6(18): 4447-4464.

[0186] The nanoparticles described herein are exemplary and non-limiting, and numerous other lipid bilayer-coated nanoparticles will be available to those of skill in the art using the teachings provided herein.

[0187] In one embodiment, the present invention teaches a nanocarrier comprising an ICD prodrug.

[0188] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, wherein the lipid comprises CHEMS.

[0189] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, wherein the lipid comprises stearic acid.

[0190] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, wherein the lipid comprises a CHEMS, and the liposome further comprises an ICD prodrug.

[0191] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, wherein the lipid comprises CHEMS, and the liposome further comprises IC1.

[0192] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, where the lipid comprises stearic acid, and the liposome further comprises an ICD-inducing agent.

[0193] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, where the lipid comprises stearic acid, and the liposome further comprises IC1.

[0194] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, where the lipid comprises stearic acid and a hydrazone, and the liposome further comprises IC1.

[0195] In one embodiment, the present invention teaches a nanocarrier comprising a liposome, where the lipid comprises stearic acid, and the liposome further comprises IC1 (referred to as LNP-IC1).

[0196] In a further embodiment, the present invention teaches a nanocarrier comprising a liposome, wherein the lipid comprises stearic acid, and the liposome further comprises IC1, and the liposome is co-formulated with a toll-like receptor agonist, wherein the toll-like receptor agonist comprises a toll-like receptor agonist designated TR12 (designated LNP-IC1-TR12).

[0197] In a preferred embodiment, the lipid particle comprises a solid lipid nanoparticle (SLNP) that comprises a liposome containing an ICD prodrug.

[0198] In one embodiment, the present invention teaches a nanocarrier comprising a solid lipid nanoparticle ("SLNP"), wherein the solid lipid nanoparticle comprises doxorubicin (referred to as SLNP-Dox).

[0199] In a preferred embodiment, the lipid particle comprises a solid lipid nanoparticle (SLNP) comprising a liposome comprising an ICD prodrug, where the ICD prodrug comprises IC1.

[0200] In one embodiment, the present invention teaches a nanocarrier comprising a solid lipid nanoparticle ("SLNP"), wherein the solid lipid nanoparticle comprises stearic acid, and the solid lipid nanoparticle further comprises IC1 (referred to as SLNP-IC1).

[0201] In a further embodiment, the present invention teaches a nanocarrier comprising SLNPs, wherein the lipid comprises stearic acid, and the SLNPs further comprise IC1, and the SLNPs are co-formulated with a toll-like receptor agonist, wherein the toll-like receptor agonist comprises a toll-like receptor agonist designated TR12 (designated as SLNP-IC1-TR12).

[0202] In a further embodiment, the present invention teaches a nanocarrier comprising SLNP, wherein the lipid comprises stearic acid, the SLNP further comprises IC1, and the SLNP is co-formulated with RGD peptide (referred to as SLNP-IC1-RGD).

[0203] In a further preferred embodiment, the solid lipid nanoparticles of the present invention have the following ratio: [Table 1] The composition includes a composition having the formula:

[0204] In a further preferred embodiment, the solid lipid nanoparticles of the present invention have the following ratio: [Table 2] The composition includes a composition having the formula: wherein lipid 1 comprises an IC1 prodrug, the lipid moiety comprises stearic acid, the helper lipid is a helper lipid described in Table II, the stabilizer is selected from the group consisting of polyvinyl alcohol (e.g., Moliwol 488), poloxamer (e.g., Pluronic® F127), Tween® 80, PEG400, and Kolliphor RH 40, and lipid 2 and lipid 3 (lipid prodrugs) comprise a lipid prodrug of the present disclosure or a lipid prodrug selected from the group consisting of ID3, PD3, TR3, TB4 inhibitors (e.g., ID3-STEA, ID3-CHEM, PD3-STEA, TR3-STEA, TB4-STEA, etc.), MPLA, and telluratomod.

[0205] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0206] The scope of the present disclosure teaches three potential treatment modalities using the formulated prodrugs of the present invention. See PCT Patent Publication No. WO2018 / 213631.

[0207] The first treatment modality involves the combination of an ICD prodrug in combination with another therapeutic agent (e.g., another formulated prodrug that induces ICD, and other family members, additional chemotherapeutic agents (e.g., ICD-inducing chemotherapy), etc.) into a single liposome that allows for systemic (or local) biodistribution and drug delivery to the tumor site. The dual delivery approach achieves synergistic enhancement of adaptive and innate immunity, resulting in significant improvements in animal survival. In certain embodiments, the nanocarrier comprises a vesicle (i.e., a lipid bilayer encapsulating a fluid).

[0208] A second treatment modality involves localized delivery to the tumor or peritumoral area of ​​a combination of an agent that induces ICD and / or a lipid (e.g., liposome) containing an additional agent that induces ICD of other family members.

[0209] The third treatment modality involves vaccination with dying cancer cells (e.g., KPC cells), and ICD is induced ex vivo.It has been discovered that such vaccination can generate a systemic immune response that can block tumor growth at distant sites, and allows for adoptive transfer to non-immunized animals.Those skilled in the art will be able to understand and carry out the methods of the treatment modalities provided herein.

[0210] VII.) Liposomes In one aspect, the subject matter of the present disclosure is based on an approach to provide the ICD prodrugs of the present disclosure (see the section entitled "Prodrugs") suitable for incorporation into nanocarriers that include a lipid coating layer to provide enhanced delivery of the corresponding prodrug, and to provide combination therapy that includes the prodrug.The advantages of using the prodrugs of the present disclosure include facilitating controlled formulation into the LNPs (e.g., liposomes) of the present disclosure.This allows the prodrugs to remain in an inactive form during systemic circulation, which allows the liposomes to release the active agent after being taken up by cells, for example, in tumors.

[0211] In certain embodiments, one or more ICD prodrugs (e.g., any one or more of the ICD prodrug inhibitors taught in this disclosure and / or an IC1 prodrug) (see the section entitled Prodrugs) are formulated into a lipid moiety that can form a vesicular (e.g., liposomal) structure in aqueous solution or form a component of the lipid bilayer that comprises a liposome. The liposomes may be used directly or may be provided as a component in a combination formulation (e.g., in combination with another drug moiety or therapeutic modality disclosed herein).

[0212] In certain embodiments, the liposomes formulated with the ICD prodrug contain lipids, PHGP, vitamin E, cholesterol, and / or fatty acids.

[0213] In one embodiment, the liposome comprises cholesterol.

[0214] In one embodiment, the liposome comprises DSPC.

[0215] In one embodiment, the liposome comprises HSPCs.

[0216] In one embodiment, the liposome is DSPE-PEG 2000 Includes.

[0217] In one embodiment, the liposome comprises DPPG.

[0218] In one embodiment, the liposome comprises DMPG.

[0219] In one embodiment, the liposome comprises Lyso PC.

[0220] In one embodiment, the liposome comprises (Δ9-Cis)PG.

[0221] In one embodiment, the liposome comprises Soy Lyso PC.

[0222] In one embodiment, the liposome comprises PG.

[0223] In one embodiment, the liposome comprises PA-PEG3-mannose.

[0224] In one embodiment, the liposome comprises C16 PEG2000 ceramide.

[0225] In one embodiment, the liposome comprises MPLA.

[0226] In one embodiment, the liposomes comprise CHEMS.

[0227] In one embodiment, the liposomes comprise stearic acid.

[0228] In one embodiment, the liposomes comprise a phospholipid as set forth in Table III.

[0229] In one embodiment, a liposome comprises IC1, further comprises CHEMS, and further comprises LU, wherein said LU is a hydromethylcarbamate linker.

[0230] In one embodiment, the liposome comprises IC1, further comprises stearic acid, and further comprises LU, wherein said LU is a hydromethylcarbamate linker.

[0231] In one embodiment, the liposome comprises IC1, further comprises stearic acid, and further comprises LU, wherein said LU is a hydrazone linker.

[0232] In one embodiment, the liposome comprises IC1, further comprises CHEMS, and further comprises LU, wherein said LU is a hydromethylcarbamate linker, and further comprises a helper lipid as described in Table II.

[0233] In one embodiment, the liposome comprises IC1, further comprises stearic acid, further comprises LU, said LU being a hydromethylcarbamate linker, and further comprises a helper lipid described in Table II.

[0234] In one embodiment, the liposome comprises IC1, further comprises stearic acid, and further comprises LU, wherein said LU is a hydrazone linker, and further comprises a helper lipid described in Table II.

[0235] In one embodiment, the liposomes of the present disclosure comprise an ICD prodrug co-formulated with one or more additional immunomodulatory agents, including but not limited to chemotherapeutic agents that induce immunogenic cell death, toll-like receptor agonists, sting agonists, IDO inhibitors, CTLA4 inhibitors, PD-1 inhibitors, and / or prodrugs thereof.

[0236] In a preferred embodiment, the liposomes contain an IC1 prodrug co-formulated with a chemotherapeutic drug that induces ICD.

[0237] In a preferred embodiment, the liposome comprises an ICD prodrug co-formulated with an ICD-inducing chemotherapeutic agent selected from the following list: doxorubicin (DOX), mitoxantrone (MTO), oxaliplatin (OXA), cyclophosphamide (CP), bortezomib, carfilzimib, or paclitaxel.

[0238] In a preferred embodiment, the liposome comprises an ICD prodrug co-formulated with a Toll-like receptor TLR agonist / prodrug.

[0239] In a preferred embodiment, the liposome comprises an ICD prodrug co-formulated with a Toll-like receptor (TLR) agonist / prodrug selected from the following list: TR12, resiquimod (R848), gardquimod, 852A, DSR 6434, telluritolimod, CU-T12-9, monophosphoryl lipid A (MPLA), 3D(6-acyl)-PHAD®, SMU127, Pam3CSK4, or 3D-PHAD®, or a prodrug thereof.

[0240] In a preferred embodiment, the liposome contains an ICD prodrug co-formulated with a PD-1 inhibitor / prodrug.

[0241] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with a PD-1 inhibitor / prodrug selected from the following list: PD3, AUNP12, CA-170, or BMS-986189, or a prodrug thereof.

[0242] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with an IDO-1 inhibitor / prodrug.

[0243] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with an IDO-1 inhibitor / prodrug selected from the following list: ID3, epacadostat, L-1-methyltryptophan (indoximod), D-1-methyltryptophan, linrodostat mesylate (BMS 986205), MK-7162, LY-3381916, KHK-2455, HTI-1090, DN-1406131, or BGB-5777.

[0244] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with doxorubicin (DOX).

[0245] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with mitoxantrone (MTO).

[0246] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with doxorubicin (DOX) and a PD-1 prodrug.

[0247] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with mitoxantrone (MTO) and a PD-1 prodrug.

[0248] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with doxorubicin (DOX) and an IDO-1 prodrug.

[0249] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with mitoxantrone (MTO) and an IDO-1 prodrug.

[0250] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with doxorubicin (DOX) and a TLR agonist / prodrug.

[0251] In a preferred embodiment, the liposomes contain mitoxantrone (MTO) and an ICD prodrug co-formulated with the TLR agonist / prodrug.

[0252] In a preferred embodiment, the liposomes contain doxorubicin (DOX) and an ICD prodrug co-formulated with a PD-1 prodrug and a TLR agonist / prodrug.

[0253] In a preferred embodiment, the liposomes contain mitoxantrone (MTO) and an ICD prodrug co-formulated with a PD-1 prodrug and a TLR agonist / prodrug.

[0254] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with a TLR agonist / prodrug.

[0255] In a preferred embodiment, the liposome contains an ICD prodrug co-formulated with a TGFb inhibitor / prodrug.

[0256] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with an IDO antagonist / prodrug.

[0257] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with a CTLA4 agonist / prodrug.

[0258] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with a TLR agonist / prodrug and a PD-1 prodrug.

[0259] In a preferred embodiment, the liposomes contain an ICD prodrug co-formulated with a TLR agonist / prodrug and an IDO-1 prodrug.

[0260] In a preferred embodiment, the liposomes contain the IC1 prodrug co-formulated with mitoxantrone (MTO).

[0261] In a preferred embodiment, the liposomes contain IC1 prodrugs co-formulated with doxorubicin (DOX) and / or IDO prodrugs and / or TLR agonists / prodrugs.

[0262] In a preferred embodiment, the liposomes contain mitoxantrone (MTO) and / or IDO prodrugs and / or IC1 prodrugs co-formulated with TLR agonists / prodrugs.

[0263] Those skilled in the art will recognize and understand that solubility is one of the most common problems that engineers face in drug development process.Chemical conjugation of drugs / anticancer drugs via lipid molecules (i.e., lipid-based prodrugs) provides a platform to solve the problem of formulating drugs in aqueous suspension.The main advantage of using lipid conjugation (lipid-based prodrugs) to deliver drugs relies on its ability to improve pharmacokinetics / half-life and targeted delivery.

[0264] By suitable selection of lipid molecules, lipid-based prodrugs can be incorporated / formulated into liposomal preparations using techniques known in the art, which have many advantages over traditional drug delivery systems. (KOHLI, et. al., J. Control Release, 0: pp 274-287 (Sept. 28, 2014), and GARCIA-PINEL, et. al., Nanomaterials 9:638 (2019). The advantage of combining lipid prodrugs with liposomes is twofold: (i) liposomes containing lipid prodrugs not only increase the solubility of the drug / prodrug itself, but also (ii) have the ability to encapsulate multiple drugs (both hydrophilic and lipophilic) (see the section entitled Nanocarriers).

[0265] For the purposes of this disclosure, the primary advantages of liposomal formulations are: i) The liposome formulation is biocompatible / biodegradable and has no general toxicity. ii) Flexibility in size and surface charge and their manipulation depending on the required purpose. Liposomal formulations, for the purposes of this disclosure, may have diameters in the size range of 40 to 150 nm, and surface charges in the range of -40 to +40 mV. iii) The liposomes of the present invention have single or multiple lipid prodrugs as the constituent lipid moieties of the liposome. In addition, multiple drugs (e.g., those that function by different mechanisms of action) and different solubility profiles (hydrophilicity or lipophilicity) can be formulated in these liposomes (either in the lipid bilayer or in the hydrophilic core).

[0266] As will be appreciated by those skilled in the art, all methods of making liposomes include four basic stages: (i) drying the lipids from the organic solvent; (ii) dispersing lipids in an aqueous solution; (iii) purifying the resulting liposomes; and (iv) Analyzing the final product. See AKBARZADEH, et. al., Nanoscale Research Letters, 8:102 (2013).

[0267] Another aspect of the present invention discloses liposome encapsulation technology (LET), a delivery technique used to transport drugs. LET is a method of producing submicroscopic foams called liposomes that encapsulate a number of materials. These "liposomes" form a barrier around the contents that is resistant to oral and gastric enzymes, alkaline solutions, digestive fluids, bile salts, and intestinal flora, as well as free radicals produced in the human body. The contents of the liposome are therefore protected from oxidation and degradation. This protective phospholipid shield or barrier remains intact until the contents of the liposome are delivered to the exact target gland, organ, or system where they will be utilized (see the section entitled Nanocarriers).

[0268] In one embodiment, the liposomes of the present disclosure are synthesized using multiple different ratios of ICD prodrug, lipid, and / or lipid prodrug. As disclosed herein, the ICD prodrug can include a helper lipid as disclosed herein (see, e.g., Table II).

[0269] In one embodiment, the liposomes of the present disclosure are synthesized using multiple different ratios of ICD prodrug, lipid, and / or lipid prodrug. As disclosed herein, the ICD prodrug can further include DSPE-PEG.

[0270] In a preferred embodiment, the liposomes of the present invention have the following ratio: [Table 3] The composition includes a composition having the formula:

[0271] In a further preferred embodiment, the liposomes of the present invention have the following ratio: [Table 4] The composition includes a composition having the formula:

[0272] In a further preferred embodiment, the liposomes of the present invention have the following ratio: [Table 5] The composition includes a composition having the formula: Here, lipid 1 comprises the IC1 prodrug and the lipid moiety comprises CHEMS.

[0273] In a further preferred embodiment, the liposomes of the present invention have the following ratio: [Table 6] The composition includes a composition having the formula: Here, lipid 1 contains the IC1 prodrug and the lipid portion contains stearic acid.

[0274] In a further preferred embodiment, the liposomes of the present invention have the following ratio: [Table 7] The composition includes a composition having the formula: wherein lipid 1 comprises an IC1 prodrug, the lipid moiety comprises stearic acid, and lipid 2 and lipid 3 (lipid prodrugs) comprise a lipid prodrug of the present disclosure or a lipid prodrug selected from the group consisting of ID3, PD3, TR3, TR12, RGD, and TB4 inhibitors (e.g., ID3-STEA, ID3-CHEM, PD3-STEA, TR3-STEA, TB4-STEA, etc.), MPLA, and telluratomod.

[0275] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0276] VIII.) Pharmaceutical Formulation As used herein, the term "drug" is synonymous with "medicine." In certain embodiments, the nanocarriers of the present disclosure are manufactured into encapsulated dosage forms and provided to patients for the treatment of disease.

[0277] Generally speaking, pharmaceutical formulation is the process of combining different chemicals into pure drug substances to produce a final drug product. Formulation studies involve developing a preparation of the drug that is stable and tolerated by patients. For drugs taken orally, this usually involves incorporating the drug into a tablet or capsule. It is important to understand that dosage forms contain a variety of other substances apart from the drug itself, and studies need to be conducted to ensure that the drug is compatible with these other substances.

[0278] Excipients are inert substances used as carriers for the active ingredient of a drug product, in this case the nanocarriers containing the ICD prodrug. In addition, excipients can be used to aid in the process by which the drug product is manufactured. The active ingredient is therefore dissolved in or mixed with the excipient. Excipients may also be used to bulk up formulations with highly potent active ingredients to allow for convenient and accurate dosing. Once an active ingredient is purified, it cannot remain in purified form for long periods of time. Often it will denature, go out of solution, or stick to the sides of the container.

[0279] To stabilize the active ingredient, excipients are added to ensure that the active ingredient remains active and stable long enough for the product's shelf life to be competitive with other products and safe for the end user. Examples of excipients include, but are not limited to, anti-adhesive agents, binders, coating agents, disintegrants, fillers, diluents, flavoring agents, coloring agents, lubricants, and preservatives. The final formulation includes the active ingredient and excipients, which are then encapsulated into a pharmaceutical dosage form.

[0280] Preformulation involves characterization of the physical, chemical, and mechanical properties of the drug to select which other components should be used in the preparation. Formulation studies then consider factors such as stability, particle size, polymorphism, pH, and solubility, as these factors can all affect the bioavailability and therefore activity of the drug. The drug must be combined with the inert additives in a manner that ensures that the amount of drug present is consistent in each dosage unit (e.g., each vial). The dosage form should have a uniform appearance.

[0281] These studies are unlikely to be complete by the time clinical trials begin. This means that simple preparations are first developed for use in Phase I clinical trials. These typically consist of vials, manually filled capsules containing small amounts of drug, and diluents. Proof of long-term stability of these preparations is not required as they are used (tested) within a few days. However, long-term stability is crucial in supply chain management as the time between when the final preparation is packaged and when it reaches the patient can be months or years. Consideration should be given to what is called the drug load (i.e., the ratio of active drug to the total content of the dose). Low drug loads can cause homogeneity problems. High drug loads can result in flow problems or require large capsules if the compound has a low bulk density. By the time Phase III clinical trials are reached, the drug's formulation needs to have been developed to be close to the preparation that will ultimately be used in the market.

[0282] Knowledge of stability is essential at this stage, and conditions must be developed that ensure that the drug is stable in the preparation. If the drug proves unstable, the results from the clinical trial will be invalid since it will be impossible to know what the dose administered actually was. Stability studies are performed to test if temperature, humidity, oxidation, or photolysis (ultraviolet or visible light) have any effect, and the preparation is analyzed to see if any degradation products are formed. It is also important to see if there are any undesirable interactions between the preparation and the container. If a plastic container is used, tests are performed to see if any of the ingredients become adsorbed to the plastic, and if any plasticizers, lubricants, pigments, or stabilizers leach from the plastic into the preparation. Even the adhesive of the container label needs to be tested to make sure that it does not leach through the plastic container into the preparation. The means by which the drug is formulated can avoid some of the problems associated with oral administration. Drugs are usually taken orally as tablets or capsules. The drug (active substance) itself must be soluble in aqueous solution at a controlled rate. Factors such as particle size and crystal morphology can significantly affect dissolution. Fast dissolution is not always ideal. For example, a slow dissolution rate can extend the duration of action or avoid initial high plasma levels.

[0283] In some embodiments, the nanocarriers co-formulated with the immunomodulatory agent (e.g., liposomes or SLNPs containing an ICD prodrug) and / or liposomes or SLNPs containing an ICD prodrug are administered alone or in a mixture with a physiologically acceptable carrier (e.g., saline or phosphate buffer) selected according to the route of administration and standard pharmaceutical practice. For example, when used as an injection, the nanocarriers can be formulated as a sterile suspension, dispersion, or emulsion with a pharma- ceutically acceptable carrier. In certain embodiments, saline can be utilized as a pharma- ceutically acceptable carrier. Other suitable carriers include, for example, water, buffered water, 0.4% saline, 0.3% glycine, 5% glucose, and the like, which contain glycoproteins, e.g., albumin, lipoproteins, globulins, and the like, for enhanced stability. In compositions that include saline or other salt-containing carriers, the carrier is preferably added after nanocarrier formation. Thus, after the nanocarriers are formed and loaded with a suitable drug, the nanocarriers can be diluted in a pharma- ceutically acceptable carrier, e.g., saline. Similarly, the ICD prodrug liposomes or SLNPs can be incorporated into a carrier that facilitates suspension (eg, emulsification, dilution, etc.) of the nanomaterial.

[0284] Pharmaceutical compositions can be sterilized by conventional well-known sterilization techniques. The resulting aqueous solutions, suspensions, dispersions, emulsions, etc. can be packaged for use or filtered under aseptic conditions. In certain embodiments, drug delivery nanocarriers (e.g., nanoparticles coated with LNP or SLNP) are lyophilized, and the lyophilized preparation is combined with a sterile aqueous solution before administration. The composition can also contain pharma- ceutically acceptable auxiliary substances required to fine-tune physiological conditions, such as pH adjusting and buffering agents, isotonicity agents, etc., such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.

[0285] Additionally, in certain embodiments, the pharmaceutical formulation may include lipid protective agents that protect lipids from damage due to free radicals and lipid peroxidation during storage. Lipophilic free radical quenchers, such as alpha-tocopherol, and water-soluble iron-specific chelators, such as ferrioxamine, are suitable and contemplated herein. The concentration of nanocarriers (e.g., SLNPs or liposomes containing ICD prodrugs) in the pharmaceutical formulation may vary widely, e.g., less than about 0.05% by weight, usually at least about 2-5% by weight, up to 10-50% by weight, or up to 40% by weight, or up to 30% by weight, and is selected primarily by fluid volume, viscosity, and the like, depending on the particular mode of administration selected. For example, the concentration may be increased to reduce the fluid load associated with the treatment. This may be particularly desirable in patients with atherosclerosis-related congestive heart failure or severe hypertension. Alternatively, nanocarriers composed of irritating lipids may be diluted to low concentrations to reduce inflammation at the site of administration. The amount of nanocarrier administered will depend on the particular drug used, the disease state being treated, and the judgment of the physician, but will generally be from about 0.01 to about 50 mg per kilogram of body weight, preferably from about 0.1 to about 5 mg per kg of body weight.

[0286] One of ordinary skill in the art will understand that the exact dosage will vary depending on the particular ICD prodrug and any co-formulated immunomodulatory agent, as well as the desired pharmaceutical effect, and patient factors such as age, sex, general condition, etc. One of ordinary skill in the art can readily take these factors into account and use them to establish effective therapeutic concentrations without undue experimentation.

[0287] For administration to humans (or non-human mammals) in the curative, ameliorative, retarding, or preventative treatment of the diseases described herein, the prescribing physician will ultimately determine the dosage of the drug appropriate for a given human (or non-human) subject, which can be expected to vary depending on the age, weight, and response of the individual, as well as the nature and severity of the patient's disease. In certain embodiments, the dosage of the drug provided by the nanocarrier may be approximately equal to that utilized for the free drug. However, as mentioned above, the nanocarriers described herein can significantly reduce the toxicity of the drug administered therewith and can significantly increase the therapeutic window. Thus, in some cases, dosages that exceed those prescribed for the free drug will be utilized.

[0288] Those skilled in the art will be able to understand and make variations and modifications to the disclosed embodiments without altering the function and purpose of the invention disclosed herein, and such variations and modifications are intended to be within the scope of the present disclosure.

[0289] IX.) Combination Therapies As those skilled in the art will recognize and understand, the growth and survival of cancer cells can be influenced by multiple signal transduction pathways.Therefore, it is useful to combine different enzyme / protein / receptor inhibitors that show different priorities in the target that modulates activity to treat such conditions.Targeting more than one signal transduction pathway (or more than one biological molecule involved in one given signal transduction pathway) can reduce the possibility of drug resistance occurring in cell population and / or reduce the toxicity of treatment.

[0290] Thus, the liposome or SLNP containing the ICD prodrug of the present disclosure can be used in combination with one or more other enzyme / protein / receptor inhibitors or one or more therapies for the treatment of disease, such as cancer or infectious disease. Examples of diseases and indications that can be treated with combination therapy include those described in this disclosure. Examples of cancer include, but are not limited to, solid tumors and liquid tumors, such as blood cancers. Examples of infectious diseases include viral infections, bacterial infections, fungal infections, or parasitic infections.

[0291] For example, liposomes or SLNPs containing an ICD prodrug of the disclosure can be combined with one or more inhibitors of the following kinases for the treatment of cancer: Akt1, Akt2, Akt3, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFαR, PDGFβR, PI3K (alpha, beta, gamma, delta), ), CSFIR, KIT, FLK-II, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, TAM kinase (Axl, Mer, Ty ro3), FLT3, VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf.

[0292] In further embodiments, the liposomes or SLNPs containing the ICD prodrugs of the present disclosure can be combined with one or more of the following inhibitors for the treatment of cancer or infectious diseases. Non-limiting examples of inhibitors that can be combined with the compounds of the present disclosure for the treatment of cancer and infectious diseases include FGFR inhibitors (FGFR1, FGFR2, FGFR3, or FGFR4, e.g., INCB54828, INCB62079, and INCB63904), JAK inhibitors (JAK1 and / or JAK2, e.g., ruxolitinib, baricitinib, or INCB39110), IDO inhibitors ( e.g., epacadostat, NLG919, or BMS-986205), LSD1 inhibitors (e.g., INCB59872 and INCB60003), TDO inhibitors, PI3K-delta inhibitors (e.g., INCB50797 and INCB50465), PI3K-gamma inhibitors, e.g., PI3K-gamma selective inhibitors, Pim inhibitors (e.g., INCB53914), CSF1R inhibitors, TAM receptor tyrosine kinase inhibitors, enzymes (Tyro-3, Axl, and Mer), adenosine receptor antagonists (e.g., A2a / A2b receptor antagonists), HPK1 inhibitors, histone deacetylase inhibitors (HDACs), such as HDAC8 inhibitors, angiogenesis inhibitors, interleukin receptor inhibitors, bromo and extra-terminal family member inhibitors (e.g., bromodomain inhibitors or BET inhibitors, such as INCB54329 and INCB57643), poly ADP-ribose polymerase (PARP) inhibitors, such as rucaparib, olaparib, niraparib, veliparib, or talazoparib, arginase inhibitors (INCB01158), TGFb inhibitors, PD-1 inhibitors, PD-1 / L-1 inhibitors, PD-1 / L-2 inhibitors, CTLA-4 antagonists, and adenosine receptor antagonists, or combinations thereof.

[0293] In addition, the liposomes or SLNPs containing the ICD prodrugs of the present disclosure can be further used in combination with other methods of treating cancer, for example, by chemotherapy, radiation therapy, tumor targeted therapy, adjuvant therapy, immunotherapy, or surgery.

[0294] Examples of immunotherapies include cytokine treatments (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, adoptive T cell transfer, Toll-like receptor agonists, STING agonists, oncolytic virotherapy, and immune modulating small molecules, such as thalidomide or JAK1 / 2 inhibitors.

[0295] Liposomes or SLNPs containing an ICD prodrug may be administered in combination with one or more anti-cancer drugs, e.g., chemotherapeutic drugs, such as abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezombi, bortezomib, intravenous busulfan, oral busulfan, calsterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, destinib, sirolimus ... bin, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alpha 2a, irinotecan, lapatinib ditosylate ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, mechlorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionatephenpropionate), nelarabine, nofetumomab, olaparib, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, rucaparib, sorafenib, streptozocin, sunitinib nib, sunitinib malate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, niraparib, veliparib, talazoparib, and zoledronate.

[0296] Other anti-cancer agents include antibody therapeutics such as trastuzumab (Herceptin), antibodies against costimulatory molecules such as CTLA-4 (e.g., ipilimumab), 4-1BB (e.g., urelumab, utomirumab), antibodies against PD-1 and PD-L1 / L2, or antibodies against cytokines (IL-10, TGF-beta, etc.).

[0297] Examples of antibodies against PD-1 and / or PD-L1 / L2 that can be combined with compounds of the present disclosure for the treatment of cancer or infectious diseases, such as viral, bacterial, fungal, and parasitic infections, include, but are not limited to, nivolumab, pembrolizumab, MPDL3280A, MEDI-4736, and SHR-1210.

[0298] In addition, liposomes or SLNPs containing the ICD prodrugs of the present disclosure can be used in combination with one or more immune checkpoint inhibitors for the treatment of diseases, such as cancer or infectious diseases. Examples of immune checkpoint inhibitors include inhibitors against immune checkpoint molecules, such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1, and PD-L2.

[0299] In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, and CD137. In further embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2aR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In further embodiments, the liposomes or SLNPs comprising the ICD prodrugs provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors, and TGF beta ("TGFb") inhibitors.

[0300] X.) Methods for delivering nanocarriers containing ICD prodrugs to cells As is known in the art, a wide variety of compositions and methods are known in the art for killing tumor cells using prodrugs and / or nanocarriers. In the context of cancer, a typical method involves administering to a tumor-bearing mammal a biologically effective amount of an ICD prodrug of the present disclosure, and / or a nanocarrier of the present disclosure comprising an ICD prodrug.

[0301] An exemplary embodiment is a method of delivering a therapeutic agent to a cell, comprising forming an ICD prodrug by conjugating a drug moiety of the present disclosure to a lipid of the present disclosure via a linking unit, and exposing the cell to the ICD prodrug.

[0302] In one embodiment, the ICD prodrug comprises a drug moiety and a CHEMS conjugated via a LU that comprises a hydromethylcarbamate linker.

[0303] In one embodiment, the ICD prodrug comprises a drug moiety and stearic acid conjugated via a LU that comprises a hydromethylcarbamate linker.

[0304] In one embodiment, the ICD prodrug comprises a drug moiety and stearic acid conjugated via a LU that contains a hydrazone linker.

[0305] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises CHEMS conjugated via a LU that comprises a hydromethylcarbamate linker.

[0306] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises stearic acid conjugated via a LU that comprises a hydromethylcarbamate linker.

[0307] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises stearic acid conjugated via a LU that comprises a hydrazone linker.

[0308] In one embodiment, the ICD prodrug comprises an IC1 prodrug, and the lipid moiety comprises stearic acid conjugated via a LU that contains a hydrazone linker, synthesized as shown in FIG.

[0309] Another exemplary embodiment is a method of treating an individual suspected of having a metastatic cancer, comprising parenterally administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of an ICD prodrug produced by conjugating a drug moiety to a lipid of the present disclosure via a linking unit, and exposing a cell to the ICD prodrug.

[0310] In one embodiment, the ICD prodrug comprises a drug moiety and a CHEMS conjugated via a LU that comprises a hydromethylcarbamate linker.

[0311] In one embodiment, the ICD prodrug comprises a drug moiety and stearic acid conjugated via a LU that comprises a hydromethylcarbamate linker.

[0312] In one embodiment, the ICD prodrug comprises a drug moiety and stearic acid conjugated via a LU that contains a hydrazone linker.

[0313] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises CHEMS conjugated via a LU that comprises a hydromethylcarbamate linker.

[0314] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises stearic acid conjugated via a LU that comprises a hydromethylcarbamate linker.

[0315] In one embodiment, the ICD prodrug comprises an IC1 prodrug and the lipid moiety comprises stearic acid conjugated via a LU that comprises a hydrazone linker.

[0316] In one embodiment, the ICD prodrug comprises an IC1 prodrug, and the lipid moiety comprises stearic acid conjugated via a LU that contains a hydrazone linker, synthesized as shown in FIG.

[0317] The ICD prodrugs, SLNPs, liposomes, co-formulated liposomes, and co-formulated SLNPs of the present disclosure induce immunogenic cell death and are therefore useful for treating diseases and disorders associated with ICD activity and diseases and disorders associated with DAMP protein secretion. In further embodiments of the present disclosure, the ICD prodrugs, liposomes, SLNPs, or pharma- ceutically acceptable salts or stereoisomers thereof are useful for therapeutic administration to enhance, stimulate, and / or increase immunity, including enhancing responses to vaccinations, in cancer, chronic infections, or sepsis.

[0318] In further embodiments, the present disclosure provides a method for inducing ICD in a cell. The method includes administering to an individual or patient an ICD prodrug, liposome, SLNP, and / or any of the formulas described herein (e.g., IC1 and / or IC1 prodrug), or any of the ICD prodrugs, liposomes, SLNPs, and nanoencapsulated ICD inducer prodrugs listed in any of the claims and described herein, or a pharma- ceutically acceptable salt or stereoisomer thereof. The ICD prodrugs, liposomes, SLNPs, and nanoencapsulated ICD inducer prodrugs of the present disclosure can be used alone or in combination with other drugs or therapies or adjuvants or neoadjuvants for the treatment of diseases or disorders, including cancer and other diseases. For the uses and methods described herein, any of the ICD prodrugs, liposomes, SLNPs, and nanoencapsulated ICD prodrugs of the present disclosure can be used, including any of the embodiments thereof.

[0319] In addition, the ICD prodrugs, liposomes, SLNPs, and nanoencapsulated ICD prodrugs of the present disclosure induce ICD and / or T cell function, resulting in DAMP protein secretion.

[0320] In further embodiments, the disclosure provides for the treatment of individuals or patients in vivo using ICD prodrugs, liposomes, SLNPs, and nanoencapsulated ICD prodrugs, or salts or stereoisomers thereof, such that the growth of cancerous tumors is inhibited.

[0321] The ICD prodrugs, liposomal, SLNP, and nanoencapsulated ICD prodrugs, or any of the formulas described herein (e.g., IC1 prodrug), or any of the claims and described herein, or salts or stereoisomers thereof, can be used to inhibit the growth of cancerous tumors.

[0322] In the alternative, the ICD prodrugs, liposomal, SLNP, and nanoencapsulated ICD prodrugs of the present disclosure, or any of the formulas described herein, or any of the compounds listed in any of the claims and described herein (e.g., IC1 prodrugs), or salts or stereoisomers thereof, can be used in conjunction with other agents or standard cancer treatments, as described in this disclosure.

[0323] In a further embodiment, the present disclosure provides a method for inhibiting tumor cell growth in vitro, comprising contacting tumor cells in vitro with an ICD prodrug, liposome, SLNP, and nanoencapsulated ICD prodrug of the present disclosure, or any of the formulas described herein (e.g., IC1 prodrug), or an ICD prodrug, liposome, SLNP, and nanoencapsulated ICD prodrug recited in any of the claims and described herein, or a salt or stereoisomer thereof.

[0324] In a further embodiment, the present disclosure provides a method for inhibiting the growth of tumor cells in a patient, the method comprising contacting tumor cells with an ICD prodrug, liposome, SLNP, and nanoencapsulated ICD prodrug of the present disclosure, or any of the formulas described herein (e.g., IC1 prodrug), or an ICD prodrug, liposome, SLNP, and nanoencapsulated ICD prodrug recited in any of the claims and described herein, or a salt or stereoisomer thereof.

[0325] XI.) Methods of Treating Cancer and Other Immunological Disorders Another embodiment of the present disclosure is a method for treating cancer.The method comprises administering to a patient a therapeutically effective amount of a nanocarrier comprising the ICD prodrug herein (i.e., IC1 prodrug), a compound listed in any of the claims and described herein, or a salt thereof.Examples of cancer include those whose growth can be mediated using the ICD inducer and ICD prodrug of the present disclosure, and those cancers that are typically responsive to immunotherapy.

[0326] In some embodiments, the disclosure provides a method of enhancing, stimulating, and / or increasing an immune response in a patient, comprising administering to the patient a therapeutically effective amount of an ICD prodrug and / or a liposome or SLNP comprising the same (i.e., an IC1 prodrug), a compound or composition recited in any of the claims and described herein, or a salt thereof.

[0327] Non-limiting examples of cancers that can be treated using the nanocarriers comprising the ICD prodrugs of the present disclosure, the ICD prodrugs, and co-formulated liposomes or SLNPs include bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, endometrial cancer, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, soft tissue cancer, and the like. The cancers that can be treated include, but are not limited to, sarcoma of the urethra, cancer of the penis, chronic or acute leukemia, including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancer, including asbestos-induced, and combinations of the above cancers.The compounds of the present disclosure are also useful for treating metastatic cancer, particularly metastatic cancer mediated by inducing ICD.

[0328] In some embodiments, cancers that can be treated with the liposomes, SLNPs, or ICD prodrugs of the present disclosure include melanoma (e.g., metastatic malignant melanoma), kidney cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone refractory prostate adenocarcinoma), breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer, urothelial cancer (e.g., bladder), and high microsatellite instability (MSI) cancer. high In addition, the present disclosure includes refractory or recurrent malignancies whose growth can be inhibited using the liposomes, SLNPs, or ICD prodrugs of the present disclosure, or co-formulated liposomes or SLNPs.

[0329] In additional embodiments, cancers that can be treated using the formulated and / or co-formulated liposomes or SLNPs, or ICD prodrugs of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, renal cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), hematopoietic cancers (e.g., lymphoma, leukemia, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), DLBCL, mantle cell lymphoma, non-Hodgkin's lymphoma (including relapsed or refractory NHL and relapsed follicular), Hodgkin's lymphoma, or multiple myeloma), and combinations of the above cancers.

[0330] In further embodiments, cancers that can be treated using formulated and / or co-formulated liposome, SLNP, or ICD prodrugs of the present disclosure include, but are not limited to, cholangiocarcinoma, bile duct carcinoma, triple negative breast cancer, rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellular carcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma, neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma, epithelioid sarcoma, eye cancer, fallopian tube cancer, gastrointestinal cancer, gastrointestinal stromal tumor, hairy cell leukemia, intestinal cancer, pancreatic islet cell cancer, oral cavity cancer, mouth cancer, pharyngeal cancer, laryngeal cancer, lip cancer, mesothelioma, cervical cancer, nasal cavity cancer, eye cancer, intraocular melanoma, pelvic cancer, rectal cancer, renal cell carcinoma, salivary gland cancer, nasal cancer, spinal cancer, tongue cancer, tubular carcinoma, urethral cancer, and ureteral cancer.

[0331] Additionally, in some embodiments, the formulated and / or co-formulated liposome, SLNP, or ICD prodrugs of the present disclosure can be used to treat sickle cell disease and sickle cell anemia.

[0332] Additionally, in some embodiments, diseases and indications that can be treated using formulated and / or co-formulated liposome, SLNP, or ICD prodrugs of the present disclosure include, but are not limited to, hematopoietic cancers, sarcomas, lung cancer, gastrointestinal cancer, genitourinary tract cancer, liver cancer, bone cancer, nervous system cancer, gynecological cancer, and skin cancer.

[0333] Exemplary hematopoietic cancers include lymphomas and leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin's lymphoma (including relapsed or refractory NHL and relapsed follicular), Hodgkin's lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocytosis (ET)), myelodysplastic syndromes (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), and multiple myeloma (MM).

[0334] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdomyosarcoma, fibroma, lipoma, hamartoma, and teratoma.

[0335] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchial carcinoma (squamous cell, small undifferentiated cell, large undifferentiated cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondroitin hamartoma, and mesothelioma.

[0336] Exemplary gastrointestinal cancers include esophageal (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (pancreatic ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, vipoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer.

[0337] Exemplary genitourinary tract cancers include kidney (adenocarcinoma, Wilms' tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriomas, sarcomas, stromal cell carcinoma, fibroma, fibroadenoma, adenoid tumors, lipoma).

[0338] Exemplary liver cancers include hepatocarcinoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0339] Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteochondral exostosis), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor.

[0340] Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthomas, osteitis deformans), meninges (meningioma, meningeal sarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Dacros disease.

[0341] Exemplary gynecological cancers include uterus (endometrial carcinoma), cervix (cervical carcinoma, precancerous cervical dysplasia), ovary (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, carcinoma in situ, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, sarcoma botryoides (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).

[0342] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, dysplastic nevi, lipoma, hemangioma, dermatofibroma, and keloid. In some embodiments, diseases and indications that can be treated using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple-negative breast cancer (TNBC), myelodysplastic syndrome, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma.

[0343] In addition, the compounds that induce ICD via the formulated and / or co-formulated liposomes, SLNPs, or ICD prodrugs of the present disclosure can also be used to treat infectious diseases, such as viral, bacterial, fungal, and parasitic infections.

[0344] The present disclosure provides a method for treating infectious diseases, such as viral infections.The method comprises administering to a patient a therapeutically effective amount of a formulated and / or co-formulated liposome, SLNP, or ICD prodrug, or any of the formulas described herein that are listed in any of the claims and described herein (i.e., IC1 prodrug), or a salt thereof.

[0345] Examples of viruses causing infectious diseases that can be treated by the methods of the present disclosure include, but are not limited to, human immunodeficiency virus, human papilloma virus, influenza, hepatitis A, B, C, or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, and measles virus. In some embodiments, viruses causing infections that can be treated by the methods of the present disclosure include, but are not limited to, hepatitis (A, B, or C), herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum contagiosum virus, poliovirus, rabies virus, JC virus, and arboviral encephalitis virus.

[0346] In addition, the present disclosure provides a method for treating a bacterial infection, comprising administering to a patient a therapeutically effective amount of a formulated and / or co-formulated liposome, SLNP, or ICD prodrug, or any of the formulas described herein (i.e., IC1 prodrug) recited in any of the claims and described herein, or a salt thereof.

[0347] Examples of pathogenic bacteria causing infections that can be treated by the methods of the present disclosure include, but are not limited to, Chlamydia, Rickettsia, Mycobacterium, Staphylococcus, Streptococcus, Pneumococcus, Meningococcus, and Conococci, Klebsiella, Proteus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacillus, Cholera, Tetanus, Botulinum, Anthrax, Plague, Leptospira, and Lyme borreliosis.

[0348] In addition, the present disclosure provides a method for treating fungal infections, comprising administering to a patient a therapeutically effective amount of a formulated and / or co-formulated liposome, SLNP, or ICD prodrug, or any of the formulas described herein (i.e., IC1 prodrug) recited in any of the claims and described herein, or a salt thereof.

[0349] Examples of pathogenic fungi causing infections that can be treated by the methods of the present disclosure include, but are not limited to, Candida (such as albicans, krusei, glabrata, tropicalis), Cryptococcus neoformans, Aspergillus (such as fumigatus and Niger), Genus Mucorales (Mucor, absidia, rhizophus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.

[0350] Additionally, the disclosure provides a method for treating a parasitic infection comprising administering to a patient a therapeutically effective amount of a formulated and / or co-formulated liposome, SLNP, or ICD prodrug, or any of the formulae described herein recited in any of the claims and described herein (i.e., IC1 prodrug), or a salt thereof.

[0351] Examples of pathogenic parasites causing infections that can be treated by the methods of the present disclosure include, but are not limited to, Entamoeba histolytica, Balantidium coli, Naegleria fowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, and Nippostrongylus brasiliensis.

[0352] In a further set of embodiments within the scope of this disclosure, formulated and / or co-formulated liposomes, nanocarriers, SLNPs, or ICD prodrugs, or any of the formulas described herein (i.e., IC1 prodrugs), are useful for preventing or reducing the risk of developing any of the diseases mentioned in this disclosure, for example, preventing or reducing the risk of developing a disease, condition, or disorder in an individual who may have a predisposition to the disease, condition, or disorder but has not yet experienced or exhibited the pathology or symptoms of the disease.

[0353] In one embodiment, the methods described herein include LNP-IC1 and / or a therapeutically effective amount of LNP-IC1.

[0354] In one embodiment, the methods described herein include SLNP-IC1 and / or a therapeutically effective amount of SLNP-IC1.

[0355] In one embodiment, the methods described herein include SLNP-IC1-TR12 and / or a therapeutically effective amount of SLNP-IC1-TR12.

[0356] In one embodiment, the methods described herein include SLNP-IC1-RGD and / or a therapeutically effective amount of SLNP-IC1-RGD.

[0357] XII.) Kits / Articles of Manufacture Kits are within the scope of the present invention for use in the laboratory, prognostic, preventive, diagnostic, and therapeutic applications described herein. Such kits may include a carrier, package, or container that is compartmentalized to receive one or more containers, such as vials, tubes, etc., each container containing one of the separate elements to be used in the method, with a label or package insert containing instructions for use, such as the uses described herein. For example, the container may contain formulated and / or co-formulated liposomes that are detectably labeled or can be labeled, and / or loaded with the ICD prodrug of the present disclosure. The kit may include a container that contains a drug unit. The kit may include all or a portion of formulated and / or co-formulated nanocarriers, liposomes, SLNPs, and / or ICD prodrugs.

[0358] Kits of the present invention typically include the aforementioned container, as well as one or more other containers associated therewith that contain materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, carriers, packages, containers, vials, and / or tube labels indicating the contents and / or instructions for use, and package inserts with instructions for use.

[0359] A label may be present on or associated with the container to indicate that the composition is used for a particular therapeutic or non-therapeutic application, such as prognostic, preventative, diagnostic, or laboratory use, and may indicate instructions for either in vivo or in vitro use, such as those described herein. Instructions and / or other information may also be included in a package insert or label included with or in the kit. The label may be on or associated with the container. The label is on the container when letters, numbers, or other features forming the label are molded or etched into the container itself, and the label may be associated with the container, e.g., as a package insert, when it is present in a receptacle or carrier that also holds the container. The label may indicate that the composition is used to diagnose, treat, prevent, or prognose a condition, such as cancer or other immunological disorder.

[0360] The terms "kit" and "article of manufacture" may be used interchangeably.

[0361] In another embodiment of the present invention, an article of manufacture comprising the composition, such as formulated and / or co-formulated nanocarriers, liposomes, SLNPs, and / or ICD prodrugs, is within the scope of the present disclosure. The article of manufacture typically comprises at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The container can be formed from a variety of materials, such as glass, metal, or plastic. The container can hold formulated and / or co-formulated liposomes loaded with ICD prodrugs.

[0362] The container may alternatively hold a composition that is effective for treating, diagnosing, prognosing, or preventing a condition and may have a sterile access port (e.g., the container may be an intravenous bag or a vial having a stopper pierceable by a hypodermic injection needle).The active agent in the composition may be a formulated and / or co-formulated nanocarrier, liposome, or SLNP loaded with an ICD prodrug and / or an ICD prodrug disclosed herein.

[0363] The article of manufacture may further include a second container containing a pharma- ceutically acceptable buffer, such as phosphate-buffered saline, Ringer's solution, and / or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, stirrers, needles, syringes, and / or package inserts containing instructions and / or instructions for use.

[0364] In one embodiment, the kit or article of manufacture comprises LNP-IC1 and / or a therapeutically effective amount of LNP-IC1.

[0365] In one embodiment, the kit or article of manufacture comprises SLNP-IC1 and / or a therapeutically effective amount of SLNP-IC1.

[0366] In one embodiment, the kit or article of manufacture comprises SLNP-IC1-TR12 and / or a therapeutically effective amount of SLNP-IC1-TR12.

[0367] In one embodiment, the kit or article of manufacture comprises SLNP-IC1-RGD and / or a therapeutically effective amount of SLNP-IC1-RGD.

[0368] Exemplary embodiments 1) An ICD prodrug composition comprising: (i) a drug moiety; and (ii) a lipid portion; and (iii) Consolidated Unit (“LU”) and Including, the drug moiety comprises an agent that induces ICD, and the LU conjugates the drug moiety to a lipid moiety; ICD Prodrug Compositions. 2) The ICD prodrug of claim 1, wherein the drug moiety comprises the chemical structure set forth as IC1. 3) The ICD prodrug of claim 1, wherein LU is a hydrazone linker. 4) The ICD prodrug of claim 1, wherein the lipid moiety comprises a lipid described in Table I. 5) The ICD prodrug of claim 1, wherein the lipid moiety comprises a lipid described in Table III. 6) The ICD prodrug of claim 1, wherein the lipid moiety comprises CHEMS. 7) The ICD prodrug of claim 1, wherein the lipid moiety comprises stearic acid. 8) The ICD prodrug of claim 1, wherein the lipid moiety comprises stearic acid and further comprises a hydrazone. 9) The drug portion comprises the chemical structure described as IC1, the lipid portion comprises stearic acid, and the compound has the following chemical structure: [ka] 2. The ICD prodrug of claim 1, having the formula: 10) An ICD prodrug composition comprising: (i) a drug moiety comprising IC1; and (ii) a lipid moiety comprising CHEMS; (iii) LU, which comprises a hydromethylcarbamate linker; 1. An ICD prodrug composition comprising: 11) An ICD prodrug composition comprising: (i) a drug moiety comprising IC1; and (ii) a lipid portion comprising stearic acid; (iii) LU, which comprises a hydrazone linker; 1. An ICD prodrug composition comprising: 12) The following chemical structure: [ka] 12. The ICD prodrug composition of claim 11, having the formula: 13) A nanocarrier comprising an ICD prodrug, which releases a drug that induces immunogenic cell death (ICD) after LU cleavage. 14) The nanocarrier of claim 13, wherein LU is a hydrazone linker. 15) The nanocarrier of claim 13, further comprising a helper lipid as described in Table II. 16) The nanocarrier of claim 13, wherein the ICD prodrug comprises IC1. 17) The nanocarrier described in claim 13, which is a liposome. 18) The liposome of claim 17, wherein the ICD prodrug comprises IC1 and is referred to as LNP-IC1. 19) The liposome of claim 18, wherein the liposome is further co-formulated with one or more immunomodulatory agents or lipid prodrugs thereof, wherein the immunomodulatory agent is selected from the group consisting of chemotherapeutic agents that induce immunogenic cell death, toll-like receptor agonists, STING agonists, CTLA-4 inhibitors, IDO inhibitors, PD-1 / PD-L1 inhibitors, CD1D agonists, A2aR inhibitors, and / or prodrugs thereof. 20) The liposome of claim 18, wherein the liposome is further co-formulated with a chemotherapeutic agent that induces ICD, and the chemotherapeutic agent that induces ICD is selected from the group consisting of DOX, MTO, OXA, CP, bortezomib, carfildimib, or paclitaxel. 21) The liposome of claim 18, further comprising OXA. 22) The liposome of claim 18, further comprising MTO. 23) The liposome of claim 20, further comprising OXA. 24) The liposome of claim 20, further comprising MTO. 25) The liposome of claim 18, wherein the liposome is further co-formulated with a toll receptor agonist or a lipid prodrug thereof, wherein the toll receptor agonist is selected from the group consisting of resiquimod (R848), gardquimod, 852A, DSR 6434, telluritolimod, CU-T12-9, monophosphoryl lipid A (MPLA), 3D(6-acyl)-PHAD®, SMU127, Pam3CSK4, TR5, TR6, TR3, TR12, or 3D-PHAD®. 26) The liposome of claim 18, wherein the liposome is further co-formulated with a PD-1 / PD-L1 antagonist or a lipid prodrug thereof, wherein the PD-1 / PD-L1 antagonist is selected from the group consisting of AUNP12, CA-170, PD3, or BMS-986189. 27) The liposome of claim 18, wherein the liposome is further co-formulated with a TGFb antagonist, the TGFb antagonist being selected from the group consisting of TB4. 28) The liposome of claim 18, wherein the liposome is further co-formulated with an IDO inhibitor, the IDO inhibitor being selected from the group consisting of ID3. 29) The liposome of claim 18, wherein the liposome is further co-formulated with an A2aR antagonist, wherein the A2aR antagonist is selected from the group consisting of AR1, AR2, AR3, AR4, or AR5. 30) A kit comprising the nanocarrier described in any one of claims 13 to 17. 31) A kit comprising the liposome according to any one of claims 18 to 29. 32) The nanocarrier of claim 13, which is a solid lipid nanoparticle (SLNP). 33) The nanocarrier of claim 16, which is a solid lipid nanoparticle (SLNP). 34) The SLNP of claim 32, wherein the ICD prodrug comprises IC1 and is referred to as SLNP-IC1. 35) The nanocarrier described in claim 33, designated SLNP-IC1. 36) The SLNP of claim 32, wherein the SLNP is further co-formulated with one or more immunomodulatory agents or lipid prodrugs thereof, wherein the immunomodulatory agent is selected from the group consisting of chemotherapeutic agents that induce immunogenic cell death, toll receptor agonists, STING agonists, CTLA-4 inhibitors, IDO inhibitors, PD-1 / PD-L1 inhibitors, CD1D agonists, and / or prodrugs thereof. 37) The SLNP of claim 32, wherein the SLNP is further co-formulated with a chemotherapeutic agent that induces ICD, and the chemotherapeutic agent that induces ICD is selected from the group consisting of DOX, MTO, OXA, CP, bortezomib, carfildimib, or paclitaxel. 38) The SLNP of claim 31, further comprising OXA. 39) The SLNP of claim 31, further comprising MTO. 40) The SLNP of claim 33, further comprising OXA. 41) The SLNP of claim 33, further comprising MTO. 42) The SLNP of claim 32, wherein the liposome is further co-formulated with a toll receptor agonist or a lipid prodrug thereof, and the toll receptor agonist is selected from the group consisting of resiquimod (R848), gardquimod, 852A, DSR 6434, telluritolimod, CU-T12-9, monophosphoryl lipid A (MPLA), 3D(6-acyl)-PHAD®, SMU127, TR12, Pam3CSK4, or 3D-PHAD®. 43) The SLNP of claim 32, wherein the liposome is further co-formulated with a PD-1 / PD-L1 antagonist or a lipid prodrug thereof, wherein the PD-1 / PD-L1 antagonist is selected from the group consisting of AUNP12, CA-170, or BMS-986189. 44) The SLNP of claim 32, wherein the SLNP is further co-formulated with a PD-1 / PD-L1 antagonist or a lipid prodrug thereof, wherein the PD-1 / PD-L1 antagonist is selected from the group consisting of AUNP12, CA-170, PD3, or BMS-986189. 45) The SLNP of claim 32, wherein the SLNP is further co-formulated with a TGFb antagonist, wherein the TGFb antagonist is selected from the group consisting of TB4. 46) The SLNP of claim 32, wherein the SLNP is further co-formulated with an IDO inhibitor, the IDO inhibitor being selected from the group consisting of ID3. 47) The SLNP of claim 12, wherein the SLNP is further co-formulated with an A2aR antagonist, wherein the A2aR antagonist is selected from the group consisting of AR1, AR2, AR3, AR4, or AR5. 48) A kit comprising the SLNP according to any one of claims 32 to 47. 49) A method of treating a subject suffering from or diagnosed with cancer, comprising: (i) administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises an ICD prodrug; and (ii) a pharma- ceutically acceptable salt thereof; A method comprising: 50) The method of claim 49, wherein the ICD prodrug comprises an IC1 prodrug. 51) The method of claim 49, wherein the nanocarrier further comprises an IC1 prodrug co-formulated with a toll-like receptor. 52) The method of claim 49, wherein the nanocarrier further comprises an IC1 prodrug co-formulated with an immunomodulatory agent. 53) The method of claim 49, wherein the nanocarrier is a liposome. 54) The method of claim 49, wherein the liposome is LNP-IC1. 55) The method of claim 49, wherein the nanocarrier is a solid lipid nanoparticle. 56) The method of claim 55, wherein the SLNP is SLNP-IC1. 57) The method of claim 56, wherein SLNP-IC1 is used in combination with a PD-1 antibody, a CTLA4 antibody, or a chemotherapeutic agent that induces immunogenic cell death (e.g., OXA or MTO). 58) A method of treating a subject suffering from or diagnosed with cancer, comprising: (i) administering to a subject in need of such treatment an effective amount of a nanocarrier, wherein the nanocarrier comprises an ICD prodrug; and (ii) a pharma- ceutically acceptable salt thereof; A method comprising: 59) The method of claim 58, wherein the ICD prodrug comprises an IC1 prodrug. 60) The method of claim 58, wherein the nanocarrier further comprises an IC1 prodrug co-formulated with a toll-like receptor. 61) The method of claim 58, wherein the nanocarrier further comprises an IC1 prodrug co-formulated with an immunomodulatory agent. 62) The method of claim 58, wherein the nanocarrier is a solid lipid nanoparticle ("SLNP"). 63) The method of claim 62, wherein the SLNP is SLNP-IC1. 64) The method of claim 58, wherein the nanocarrier is a liposome. 65) The method of claim 64, wherein the liposome is LNP-IC1. 66) The chemical structure: [ka] The IC1 prodrug having the formula: 67) A liposome comprising the IC1 prodrug described in claim 66. 68) A liposome comprising the IC1 prodrug of claim 67, further comprising a helper lipid. 69) The liposome of claim 68, wherein the helper lipid is listed in Table II. 70) A solid lipid nanoparticle (SLNP) comprising the IC1 prodrug of claim 66. 71) The liposome described in claim 67, referred to as LNP-IC1. 72) The SLNP of claim 70, designated SLNP-IC1. 73) The SLNP of claim 72, co-formulated with TR12. 74) The SLNP of claim 72, co-formulated with RGD. 75) A composition comprising a solid lipid nanoparticle (SLNP), wherein the SLNP further comprises IC1 co-formulated with TR12 (referred to as SLNP-IC1-TR12). 76) A composition comprising a solid lipid nanoparticle (SLNP), wherein the SLNP further comprises IC1 co-formulated with RGD (referred to as SLNP-IC1-RGD). EXAMPLES

[0369] Various aspects of the present invention are further described and illustrated by means of several examples below, none of which are intended to limit the scope of the invention.

[0370] Example 1 Chemical synthesis of IC1 prodrugs containing stearic acid and hydrazone. Chemical synthesis of IC1 prodrug containing stearic acid and hydrazone was synthesized using the following protocol. Briefly, to a solution of doxorubicin (11.0 g, 18.9 mmol, 1.00 equiv.) and stearic acid hydrazide (16.9 g, 56.9 mmol, 3.00 equiv.) in MeOH (440 mL), TFA (10.1 g, 89.1 mmol, 6.60 mL, 4.70 equiv.), PTSA (4.40 g, 25.5 mmol, 1.35 equiv.), and molecular sieves 4A (44.0 g) were added. The reaction mixture was then stirred at 55° C. for 12 h. LCMS confirmed that most of the doxorubicin (RT=0.786 min) was consumed and 83% of the desired mass (RT=1.111 min) was detected. The mixture was filtered to obtain a filtrate. The filtrate was purified by normal phase HPLC (column: Welch Ultimate XB-SiOH 250×50×10um, mobile phase: [Hexane-EtOH (0.1% NH3.H2O)]; B%: 10%-50%, 15 min) to give the crude product, which was triturated with EtOH (50.0 mL). Doxorubicin stearate-hydrazone (2.50 g, 2.96 mmol, 15.6% yield, 97.6% purity) was obtained as a reddish orange solid, which was 1 The synthesis described in this example yielded the following chemical structure: [ka] The IC1 prodrug is obtained which comprises a stearic acid hydrazone having the formula:

[0371] Example 2 Synthesis and characterization of SLNP-IC1 solid lipid nanoparticles. In another experiment, solid lipid nanoparticles containing IC1 (referred to as SLNP-IC1) were synthesized by solvent diffusion with and without stabilizers. Polyvinyl alcohol (e.g., Moliwol 488), poloxamers (e.g., Pluronic® F-68, Pluronic® F-127), Tween® 80 and 20, and Kolliphor RH40, etc.) can be used as stabilizers. In the first step, lipid stock solutions of DSPC, cholesterol (CHOL), and DSPE-PEG were prepared in ethanol (2.5 mg / ml). Separately, IC1 prodrug stock solutions were prepared in ethanol (2.5 mg / ml). A lipid mixture was obtained by mixing DSPC, CHOL, IC1, and DSPE-PEG in a molar ratio of 33:55:7:5 (at a lipid concentration of approximately 20 mg / ml). This lipid mixture was then heated at 40-45 degrees Celsius. Similarly, the aqueous phase containing the appropriate stabilizer (e.g., 2% w / v Pluronic® F127) was heated using a magnetic heating plate stirrer with constant magnetic stirring (300-400 rpm). SLNPs can be synthesized using only DI water (without stabilizers) in the aqueous phase. The lipid mixture was slowly mixed with this aqueous phase under constant stirring. After mixing was completed, the entire mixture was sonicated for about 5 minutes using a water sonication bath and then kept on the magnetic stirrer plate with constant stirring for about an additional hour. Finally, the solvent was removed for at least 4-6 hours using a dialysis membrane (Sigma Aldrich) with a size cutoff of 12 KDa against DI water. The dialysis water was changed at least three times during this period. SLNP-IC1 was concentrated, if necessary, using an Amicon centrifugal filtration device (cutoff size 10 KDa at 3000 g).

[0372] Characterization of SLNP-IC1 was determined using a Malvern Zetasizer (Malvern Instrumentation Co., Westborough, MA, USA). Briefly, 2 ml of SLNP-IC1 (where the liposome concentration was 0.5-1 mg / ml) was placed in a four-sided clear plastic cuvette and analyzed directly at 25 °C. The results shown in Figure 5 indicate that the Zav size of the nanoparticles was approximately 99.00 nm and the PDI was approximately 0.161.

[0373] In addition, the zeta potential of SLNP-IC1 solid lipid nanoparticles in aqueous dispersion was determined using a Malvern zeta seizer instrument (Malvern Instrumentation Co, Westborough, MA, USA). Briefly, approximately 1 ml of SLNP (in DI water, at a concentration of approximately 3 mg / ml) was placed in a disposable capillary zeta potential cell available for the Zetasizer. Measurements were performed at 25° C. The results show that the zeta potential determination of SLNP-IC1 was approximately −11.2 mV ( FIG. 6 ).

[0374] Example 3 Synthesis and characterization of SLNP-IC1-RGD solid lipid nanoparticles. In another experiment, solid lipid nanoparticles (referred to as SLNP-IC1-RGD) containing IC1 co-formulated with DSPE-PEG-RGD ("RGD") were synthesized by solvent diffusion using various types of stabilizers. Polyvinyl alcohol (e.g., Moliwol 488), poloxamers (e.g., Pluronic® F-68, Pluronic® F-127), Tween® 80 and 20, and Kolliphor RH40, etc.) can be used as stabilizers. Briefly, in the first step, lipid stock solutions of DSPC, CHOL, DSPE-PEG, and DSPE-PEG-RGD were prepared in ethanol (20 mg / ml). Separately, IC1 prodrug stock solution was prepared in ethanol (2.5 mg / ml). A lipid mixture was obtained by mixing DSPC, CHOL, IC1, and DSPE-PEG, and DSPE-PEG-RGD in a molar ratio of 33:54:7:5.1 (at a lipid concentration of approximately 20 mg / ml). This lipid mixture was then heated at 40-45 degrees Celsius. Similarly, an aqueous phase containing a suitable stabilizer (e.g., 5% w / v Pluronic® F127) was heated using a magnetic heating plate stirrer with constant magnetic stirring (300-400 rpm). SLNPs can be synthesized using only DI water (without stabilizers) in the aqueous phase. The lipid mixture was slowly mixed with this aqueous phase under constant stirring. After mixing was completed, the entire mixture was sonicated for about 5 minutes using a water sonication bath and then kept on the magnetic stirrer plate with constant stirring for about an additional hour. Finally, the solvent was removed using a dialysis membrane (Sigma Aldrich) with a size cutoff of 12 KDa for DI water for at least 4-6 hours. Dialysis water was changed at least three times during this period. SLNP-IC1-RGD was concentrated, if necessary, using Amicon centrifugal filtration devices (cut-off size 10 KDa at 3000 g).

[0375] The characterization of SLNP-IC1-RGD was determined using a Malvern Zetasizer (Malvern Instrumentation Co., Westborough, MA, USA). Briefly, 2 ml of SLNP-IC1-RGD (where the liposome concentration was 0.5-1 mg / ml) was placed in a four-sided clear plastic cuvette and analyzed directly at 25 °C. The results shown in Figure 7 indicate that the Zav size of the nanoparticles was approximately 102 nm and the PDI was approximately 0.149.

[0376] In addition, the zeta potential of SLNP-IC1-RGD solid lipid nanoparticles in aqueous dispersion was determined using a Malvern zeta seizer instrument (Malvern Instrumentation Co, Westborough, MA, USA). Briefly, approximately 1 ml of SLNP (in DI water, at a concentration of approximately 3 mg / ml) was placed in a disposable capillary zeta potential cell available for the Zetasizer. Measurements were performed at 25° C. The results show that the zeta potential determination of SLNP-IC1-RGD was approximately −9.9 mV ( FIG. 8 ).

[0377] Example 4 Synthesis and characterization of SLNP-Dox solid lipid nanoparticles. In another experiment, solid lipid nanoparticles containing doxorubicin (referred to as SLNP-Dox) were synthesized by solvent diffusion using various kinds of stabilizers. Polyvinyl alcohol (e.g., Moliwol 488), poloxamers (e.g., Pluronic® F-68, Pluronic® F-127), Tween® 80 and 20, and Kolliphor RH40, etc.) can be used as stabilizers. In the first step, lipid stock solutions of DSPC, cholesterol, and DSPE-PEG were prepared in ethanol (20 mg / ml). Separately, doxorubicin stock solutions were prepared in DMSO (20 mg / ml). A lipid mixture was obtained by mixing DSPC, cholesterol, doxorubicin, and DSPE-PEG in a molar ratio of 33:54:8:5 (at a lipid concentration of approximately 20 mg / ml). This lipid mixture was then heated at 40-45 degrees Celsius. Similarly, the aqueous phase containing the appropriate stabilizer (e.g., 5% w / v Pluronic® F127) was heated using a magnetic heating plate stirrer with constant magnetic stirring (300-400 rpm). SLNPs can be synthesized using only DI water (without stabilizers) in the aqueous phase. The lipid mixture was slowly mixed with this aqueous phase under constant stirring. After mixing was completed, the entire mixture was sonicated for about 5 minutes using a water sonication bath and then kept on the magnetic stirrer plate with constant stirring for about an additional hour. Finally, the solvent was removed for at least 4-6 hours using a dialysis membrane (Sigma Aldrich) with a size cutoff of 12 KDa against DI water. The dialysis water was changed at least three times during this period. SLNP-Dox was concentrated, if necessary, using an Amicon centrifugal filtration device (cutoff size 10 KDa at 3000 g).

[0378] The characterization of SLNP-Dox was determined using a Malvern Zetasizer (Malvern Instrumentation Co., Westborough, MA, USA). Briefly, 2 ml of SLNP-Dox (wherein the liposome concentration was 0.5-1 mg / ml) was placed in a four-sided clear plastic cuvette and analyzed directly at 25°C. The results shown in Figure 9 indicate that the Zav size of the nanoparticles was approximately 91.00 nm and the PDI was approximately 0.124.

[0379] In addition, the zeta potential of SLNP-Dox solid lipid nanoparticles in aqueous dispersion was determined using a Malvern zeta seizer instrument (Malvern Instrumentation Co, Westborough, MA, USA). Briefly, approximately 1 ml of SLNP (in DI water, at a concentration of approximately 3 mg / ml) was placed in a disposable capillary zeta potential cell available for the Zetasizer. Measurements were performed at 25° C. The results show that the zeta potential determination of SLNP-Dox was approximately −10.6 mV ( FIG. 10 ).

[0380] Example 5 Synthesis and characterization of SLNP-IC1-TR12 (NTI 121) solid lipid nanoparticles. In another experiment, solid lipid nanoparticles containing IC1 co-formulated with TR12 (referred to as SLNP-IC1-TR12) were synthesized by solvent diffusion using various kinds of stabilizers. Polyvinyl alcohol (e.g., Moliwol 488), poloxamers (e.g., Pluronic® F-68, Pluronic® F-127), Tween® 80 and 20, and Kolliphor RH40, etc.) can be used as stabilizers. Briefly, in the first step, lipid stock solutions of DSPC, CHOL, and DSPE-PEG were prepared in ethanol (20 mg / ml). IC1 prodrug solution was prepared in ethanol at a concentration of 2.5 mg / ml. Separately, TR12 prodrug stock solution was prepared in DMSO (20 mg / ml). A lipid mixture was obtained by mixing DSPC, CHOL, IC1, TR12, and DSPE-PEG in a molar ratio of 33:54:56:7:0.44:5 (at a lipid concentration of approximately 20 mg / ml). This lipid mixture was then heated at 40-45 degrees Celsius. Similarly, an aqueous phase containing a suitable stabilizer (e.g., 2% w / v Pluronic® F127) was heated using a magnetic heating plate stirrer with constant magnetic stirring (300-400 rpm). SLNPs can be synthesized using only DI water (without stabilizers) in the aqueous phase. The lipid mixture was slowly mixed with this aqueous phase under constant stirring. After mixing was completed, the entire mixture was sonicated for about 5 minutes using a water sonication bath and then kept on the magnetic stirrer plate with constant stirring for about another hour. Finally, the solvent was removed using a dialysis membrane (Sigma Aldrich) with a size cutoff of 12 KDa for DI water for at least 4-6 hours. Dialysis water was changed at least three times during this period. SLNP-IC1-TR12 was concentrated, if necessary, using Amicon centrifugal filtration devices (cut-off size 10 KDa at 3000 g).

[0381] Characterization of SLNP-IC1-TR12 was determined using a Malvern Zetasizer (Malvern Instrumentation Co., Westborough, MA, USA). Briefly, 2 ml of SLNP-IC1-TR12 (wherein the liposome concentration was 0.5-1 mg / ml) was placed in a four-sided clear plastic cuvette and analyzed directly at 25°C. The results shown in Figure 11 indicate that the Zav size of the nanoparticles was approximately 102 nm and the PDI was approximately 0.166.

[0382] In addition, the zeta potential of SLNP-IC1-TR12 solid lipid nanoparticles in aqueous dispersion was determined using a Malvern zeta seizer instrument (Malvern Instrumentation Co, Westborough, MA, USA). Briefly, approximately 1 ml of SLNP (in DI water, at a concentration of approximately 3 mg / ml) was placed in a disposable capillary zeta potential cell available for the Zetasizer. Measurements were performed at 25° C. The results show that the zeta potential determination of SLNP-IC1-TR12 was approximately −11.2 mV ( FIG. 12 ).

[0383] Example 6 Serum stability / release kinetics of doxorubicin (SLNP-Dox and LNP-Dox) and IC1 (SLNP-IC1 and SLNP-IC1-RGD). In another experiment, to study the cumulative release / stability of doxorubicin at different time intervals, known amounts of various formulations (SLNP-DOX, LNP-DOX, SLNP-IC1, and SLNP-IC1-RGD) were suspended in 10 ml of 20% human serum at room temperature. At predetermined time intervals, the solution was vortexed and 1 ml aliquots were removed. To separate the released doxorubicin from the nanoformulations, the aliquots were centrifuged at 3000 rpm for 30 minutes through a membrane filter with a cutoff of 3.5 kDa. The concentration of released doxorubicin was determined using a UV-Vis Spectrophotometer (Nanodrop 2000C UV-vis spectrophotometer).

[0384] The percentage release of doxorubicin from the various nanoformulations was calculated using the following formula: Release%=([D] f,t ) / ([D]0)×100 In the formula, [D] f,t is the concentration of doxorubicin in the filtrate at time t, [D]0 is the total doxorubicin concentration (released + not released) in the nanoformulation.

[0385] From the release kinetics data, it is clear that the release of doxorubicin from SLNP-IC1 is much slower in human serum (even for incubation times up to 72 hours), indicating better stability / retention potential of doxorubicin within SLNP-IC1 in human serum. Compared to SLNP-DOX (>50% release%) and LNP-Dox (~70% release%), in the case of SLNP-IC1, less than 20% of doxorubicin was released from human serum (Figure 13).

[0386] Example 7 Cytotoxicity evaluation of IC1 in EMT-6 cells in vitro. In another experiment, the cytotoxicity of SNLP-IC1 was studied in EMT-6 mouse cell line by MTT assay using the following protocol. Briefly, EMT-6 cells were seeded in 96-well plates and incubated for 24 hours. The growth medium was then replaced with a prepared medium containing either (i) DOX (doxorubicin HCL), (ii) LNP-DOX (DOXIL (i.e., doxorubicin liposomes)), (iii) SLNP-DOX (doxorubicin in solid lipid nanocarrier form), (iv) SLNP-IC1, and (v) SLNP-IC1-RGD, each added at a medium concentration of 0, 2, 3, 6, 13, 25, 50, or 100 uM. MTT solution was added to the culture and incubated at 37°C for 4 hours. SDS-HCl solution was then added to the culture and incubated at 37°C for 4 hours. The cells were then further incubated for 24 hours and the cytotoxic activity was assessed using the MTT assay. Before reading the plate, each sample was mixed using a pipette and the absorbance was read at 570 nm to generate the optical density (OD). The % cytotoxicity was calculated using the following formula as follows: 100-(OD of test cells / OD of control cells) x 100%).

[0387] The results show that liposomal forms of Dox (LNP-Dox (i.e., DOXIL), SLNP-Dox, SLNP-IC1, and SLNP-IC1-RGD) can induce cytotoxicity in a similar manner against EMT-6 cells when compared with doxorubicin HCL free drug (Figure 14).

[0388] Example 8 Cytotoxicity evaluation of IC1 in 4T-1 cells in vitro. In another experiment, the cytotoxicity of SNLP-IC1 was studied in 4T-1 cells by MTT assay using the following protocol. Briefly, 4T-1 cells were seeded in 96-well plates and incubated for 24 hours. The growth medium was then replaced with prepared medium containing either (i) DOX (doxorubicin HCL), (ii) LNP-DOX (DOXIL (i.e., doxorubicin liposomes)), (iii) SLNP-DOX (doxorubicin in solid lipid nanocarrier form), (iv) SLNP-IC1, and (v) SLNP-IC1-RGD, each added at a medium concentration of 0, 2, 3, 6, 13, 25, 50, or 100 uM. MTT solution was added to the culture and incubated at 37°C for 4 hours. SDS-HCl solution was then added to the culture and incubated at 37°C for 4 hours. The cells were then further incubated for 24 hours and the cytotoxic activity was assessed using the MTT assay. Before reading the plate, each sample was mixed using a pipette and the absorbance was read at 570 nm to generate the optical density (OD). The % cytotoxicity was calculated using the following formula as follows: 100-(OD of test cells / OD of control cells) x 100%). The results show that liposomal forms of Dox (LNP-Dox (i.e., DOXIL), SLNP-Dox, SLNP-IC1, and SLNP-IC1-RGD) can induce cytotoxicity in a similar manner against 4T-1 cells when compared with doxorubicin HCL free drug (Figure 15).

[0389] Example 9 Tumor inhibition of SLNP-IC1 at multiple doses using EMT-6 cells in vivo.

[0390] In this study, SLNP-IC1 was evaluated in multiple combinations using the following protocol. Briefly, mouse breast cancer EMT6 cells (0.5 × 10 6Balb / c mice were inoculated with 1000 mg / kg SLNP-IC1 (1 mg / kg) subcutaneously in the right hind flank region. Animals were treated with either (i) vehicle control, (ii) 2 mg / kg SLNP-IC1, (iii) 6 mg / kg SLNP-IC1, or (iv) 2 mg / kg LNP-DOX (DOXIL (i.e., liposomal form of doxorubicin (LNP-Dox))) by intravenous injection twice a week for a total of six doses.

[0391] Tumor volumes were measured in two dimensions using calipers and volumes were calculated using the formula: V=(L×W×W)×0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Tumor growth inhibition (TGI) was calculated based on the tumor size data at day 21.

[0392] The results show that treatment with 2mg / kg SLNP-IC1 and 6mg / kg SLNP-IC1 results in significant antitumor activity when compared with vehicle control. TGI was calculated to be 88.5% (p<0.05) and 94.39% (p<0.05), respectively. In addition, SLNP-IC1 significantly inhibited tumor volume at either 2mg / kg or 6mg / kg when compared with liposomal form of doxorubicin (DOXIL). (Figure 16).

[0393] Example 10 Tumor inhibition of SLNP-IC1 at multiple doses using EMT-6 cells in vivo.

[0394] In this study, evaluation of SLNP-IC1 and co-formulated SLNP-IC1-TR12 in multiple combinations was performed using the following protocol. Briefly, mouse breast cancer EMT6 cells (0.5×10 6) were inoculated subcutaneously into the right hind flank region of Balb / c mice. Animals were treated with vehicle control, 2 mg / kg LNP-DOX (Doxil: doxorubicin in liposomal form), 0.5 mg / kg SLNP-TR12 (TR12-stearic acid in solid lipid nanoparticle form), 2 mg / kg SLNP-IC1 (doxorubicin prodrug in solid lipid nanoparticle form), and 2 / 0.5 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week for a total of six doses. Tumor volumes were measured in two dimensions using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the volume of the tumor, L is the length of the tumor (longest tumor dimension), and W is the width of the tumor (longest tumor dimension perpendicular to L). The results show that 2 mg / kg SLNP-IC1 alone or co-formulated with 0.5 mg / kg TR12 (SLNP-IC1-TR12) resulted in tumor growth inhibition. In addition, treatment with SLNP-IC1 showed improved tumor growth inhibition compared to the control LNP-DOX (Figure 17).

[0395] Example 11 Tumor inhibition of SLNP-IC1 using EMT-6 cells in vivo.

[0396] In this experiment, SLNP-IC1 was evaluated using the following protocol. Briefly, mouse breast cancer EMT6 cells (0.5 × 10 6) were inoculated subcutaneously into the right hind flank region of Balb / c mice. Animals were treated with vehicle control, 2 mg / kg SLNP-IC1 (doxorubicin prodrug in solid lipid nanoparticle form), 0.01 mg / kg SLNP-NK1 (KRN7000 in solid lipid nanoparticle form), and 2 / 0.01 mg / kg SLNP-IC1-NK1 by intravenous injection twice a week for a total of six doses. Tumor volumes were measured in two dimensions using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L).

[0397] The results show that 2 mg / kg SLNP-IC1 alone or co-formulated with 0.01 mg / kg NK1 (SLNP-IC1-NK1) resulted in tumor growth inhibition (FIG. 18).

[0398] Example 12 Tumor inhibition of SLNP-IC1 and / or SLNP-IC1-TR12 using EMT-6 cells in vivo. In this experiment, SLNP-IC1 was evaluated either alone or in combination with SLNP-IC1-TR12 using the following protocol. Briefly, mouse breast cancer EMT6 cells (0.5×10 6 ) were inoculated subcutaneously into the right hind flank region of Balb / c mice. Animals were treated with vehicle control, SLNP-IC1 (doxorubicin prodrug in solid lipid nanoparticle form), SLNP-TR12 (TR12-stearic acid in solid lipid nanoparticle form), and co-formulated SLNP-IC1-TR12. Tumor volumes were measured in two dimensions using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L).

[0399] The results show that SLNP-IC1, either as a single agent or in combination with TR12 (SLNP-IC1-TR12), at both doses resulted in tumor growth inhibition (FIG. 19).

[0400] (Example 13) Maximum tolerated dose of SLNP-IC1 and / or SLNP-IC1-TR12 in the Balb / C mouse model. In this experiment, the maximum tolerated dose ("MTD") of SLNP-IC1 was performed using the following protocol, either alone or in combination with SLNP-IC1-TR12. Briefly, balb / c mice were treated with different doses of SLNP-IC1 (SLNP form of IC1 prodrug), SLNP-TR12 (SLNP form of TR12), and SLNP-IC1-TR12 by intravenous injection. Animals were observed 30 minutes and 4 hours after injection for clinical signs of toxicity, including orbital tightening, ear position, nose bulging, lethargy, and unkempt fur. Animals were weighed 24 hours, 48 ​​hours, and 72 hours after injection.

[0401] The results show that no immediate signs of toxicity were observed in any of the groups. Of note, SLNP-IC1 alone caused slight weight loss. SLNP-TR12 also induced moderate to severe weight loss by 48 hours after injection, after which the weight loss was reversed without therapeutic intervention. Finally, the combination of SLNP-IC1 and TR12 induced a moderate weight loss that was lower than that of the SLNP-TR12-treated group (Figure 20).

[0402] Example 14 Tumor inhibition of SLNP-IC1-TR12 using B16F10 cells in vivo.

[0403] In this experiment, SLNP-IC1-TR12 was evaluated using the following protocol. Briefly, mouse melanoma B16F10 cells (cells (0.2 × 10 6) were inoculated subcutaneously into the right hind flank region of B57 / BL mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 9.

[0404] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 63.45% (Figure 21).

[0405] Example 15 Tumor inhibition of SLNP-IC1-TR12 using MPC11 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse multiple myeloma MPC11 cells (0.2 × 10 6 ) were inoculated subcutaneously into the right flank region of Balb / c mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 9.

[0406] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 53.38% (Figure 22).

[0407] Example 16 Tumor inhibition of SLNP-IC1-TR12 using Neuro2A cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse neuroblastoma Neuro2A cells (1×10 6 ) were inoculated subcutaneously into the right flank region of A / J mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data at day 10.

[0408] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 88.27% (Figure 23).

[0409] (Example 17) Tumor inhibition of SLNP-IC1-TR12 using CT26 cells in vivo.

[0410] In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse colon CT26 cells (1×10 6) were inoculated subcutaneously into the right flank region of Balb / c mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 12.

[0411] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 81.16% (Figure 24).

[0412] (Example 18) Tumor inhibition of SLNP-IC1-TR12 using MC38 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse colon MC38 cells (1×10 6 ) were inoculated subcutaneously into the right flank region of CS7 / b16 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data at day 18.

[0413] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 83.59% (Figure 25).

[0414] (Example 19) Tumor inhibition of SLNP-IC1-TR12 using kidney Renca cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse kidney Renca cells (1×10 6 ) were inoculated subcutaneously into the right flank region of Balb / c mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 13.

[0415] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 68.18% (Figure 26).

[0416] (Example 20) Tumor inhibition of SLNP-IC1-TR12 using H22 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse liver H22 cells (2×10 6) were inoculated subcutaneously into the right flank region of Balb / c mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 21.

[0417] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 100.96% (Figure 27).

[0418] Example 21 Tumor inhibition of SLNP-IC1-TR12 using Hepa1-6 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse liver Hepa1-6 cells (5×10 6 ) were inoculated subcutaneously into the right flank region of C57 / BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 16.

[0419] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 100.96% (Figure 28).

[0420] Example 22 Tumor inhibition of SLNP-IC1-TR12 using LLC1 cells in vivo.

[0421] In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse lung CCL1 cells (0.3 × 10 6 ) were inoculated subcutaneously into the right flank region of C57 / BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 16.

[0422] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 56.65% (Figure 29).

[0423] Example 23 Tumor inhibition of SLNP-IC1-TR12 using KLN205 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse lung KLN205 cells (0.8 × 10 6) were inoculated subcutaneously into the right flank region of DBA / 2 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 21.

[0424] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 64.21% (Figure 30).

[0425] (Example 24) Tumor inhibition of SLNP-IC1-TR12 using B16BL6 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse melanoma B16BL6 cells (0.2 × 10 6 ) were inoculated subcutaneously into the right flank region of C57BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 12.

[0426] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 70.51% (Figure 31).

[0427] (Example 25) Tumor inhibition of SLNP-IC1-TR12 using Pan-02.03 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse pancreatic Pan-02.03 cells (3×10 6 ) were inoculated subcutaneously into the right flank region of C57BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on tumor size data at day 62.

[0428] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 90.42% (Figure 32).

[0429] (Example 26) Tumor inhibition of SLNP-IC1-TR12 using RM-1 cells in vivo. In this study, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse prostate RM-1 cells (1×10 6) were inoculated subcutaneously into the right flank region of C57BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 14.

[0430] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 50.24% (Figure 33).

[0431] Example 27 Tumor inhibition of SLNP-IC1-TR12 using MBT-2 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse bladder MBT-2 cells (1×10 6 ) were inoculated subcutaneously into the right flank region of C3H / HE mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 16.

[0432] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 67.81% (Figure 34).

[0433] (Example 28) Tumor inhibition of SLNP-IC1-TR12 using clonal M-3 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse melanoma clone M-3 cells (0.2×10 6 ) were inoculated subcutaneously into the right flank region of C57BL6 mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volumes were measured in two dimensions in triplicate using calipers, and volumes were calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 12.

[0434] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 74.88% (Figure 35).

[0435] (Example 29) Tumor inhibition of SLNP-IC1-TR12 using 4T1 cells in vivo. In this experiment, further evaluation of SLNP-IC1-TR12 was performed using the following protocol. Briefly, mouse breast cancer 4T1 was inoculated into the mammary fat pad of Balb / c mice. Animals were treated with vehicle control or 2 / 0.25 mg / kg SLNP-IC1-TR12 by intravenous injection twice a week. Tumor volume was measured three times in two dimensions using calipers, and volume was calculated using the formula: V = (L x W x W) x 0.5, where V is the tumor volume, L is the tumor length (longest tumor dimension), and W is the tumor width (longest tumor dimension perpendicular to L). Body weight was measured three times a week. Tumor growth inhibition (TGI) was calculated based on the tumor size data on day 26.

[0436] The results show that treatment with 6 doses of SLNP-IC1-TR12 over 2 weeks results in antitumor activity compared to the vehicle-treated group. The TGI was 41.34% (Figure 36).

[0437] (Example 30) Human clinical trials for the treatment of human carcinomas through the use of formulated and / or co-formulated nanocarriers containing IC1 prodrugs.

[0438] Nanocarriers (liposomes or SLNPs) formulated and / or co-formulated with ICD prodrugs that specifically accumulate in tumor cells and are used in the treatment of certain tumors as well as other immunological disorders and / or other diseases are used in accordance with the present invention. In connection with each of these indications, two clinical approaches have been successfully pursued.

[0439] I.) Adjuvant Therapy: In adjuvant therapy, patients are treated with nanocarriers (liposomes or SLNPs) formulated and / or co-formulated with ICD prodrugs in combination with chemotherapeutic drugs or pharmaceutical or biopharmaceutical agents, or combinations thereof. Primary cancer targets are treated under standard protocols with the addition of nanocarriers (liposomes or SLNPs) formulated and / or co-formulated with ICD prodrugs. Protocol designs address efficacy as assessed by the following examples, including but not limited to reduction in tumor mass of primary or metastatic lesions, increase in progression-free survival, overall survival, improvement in patient health, disease stabilization, and ability to reduce regular doses of standard chemotherapy and other biologics. These dosage reductions allow for the addition and / or extension of therapy by reducing dose-related toxicity of chemotherapeutic drugs or biologics.

[0440] II.) Monotherapy: In connection with the use of ICD prodrug-containing formulated and / or co-formulated nanocarriers (liposomes or SLNPs) in tumor monotherapy, ICD prodrug-containing formulated and / or co-formulated nanocarriers (liposomes or SLNPs) are administered to patients without chemotherapy or pharmaceutical or biological agents. In one embodiment, monotherapy is performed clinically in late-stage cancer patients with spread metastatic disease. Protocol design addresses efficacy as assessed by the following examples, including but not limited to reduction in tumor mass of primary or metastatic lesions, increase in progression-free survival, overall survival, improvement in patient health, disease stabilization, and ability to reduce usual doses of standard chemotherapy and other biologics.

[0441] Dosage Dosage regimens can be adjusted to provide optimal desired responses. For example, a single dose of the nanocarrier (liposome or SLNP) formulated with the ICD prodrug may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. "Dosage unit form" as used herein refers to a physically discrete unit suitable as a unitary dosage for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to provide a desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of the dosage unit form of the present invention are determined by and directly depend on (a) the unique characteristics of the nanocarrier (liposome or SLNP) formulated with the ICD prodrug, (b) the individual mechanism of the combination compound, if any, (c) the specific therapeutic or prophylactic effect to be achieved, and (d) the inherent limitations in the art regarding the formulation of such compounds for the treatment of susceptibility in an individual.

[0442] Clinical Development Plan (CDP) CDP will develop and follow the procedure of using nanocarriers (liposomes or SLNPs) formulated and / or co-formulated with ICD prodrugs in conjunction with adjuvant therapy or as monotherapy. The study will first demonstrate safety and then confirm efficacy with repeated dosing. The study will be open-label and will compare nanocarriers (liposomes or SLNPs) formulated and / or co-formulated with ICD prodrugs in addition to standard chemotherapy and / or current standard treatment. As will be understood, one non-limiting criterion that can be utilized in connection with patient enrollment is DAMP proteins in tumors as determined by standard detection methods known in the art.

[0443] It is believed that the formulated and / or co-formulated nanocarriers (liposomes or SLNPs) or any of the embodiments disclosed herein may have sufficient pharmacological profiles and promising biopharmaceutical properties, such as toxicological profiles, metabolic and pharmacokinetic properties, solubility, and permeability. It is understood that the determination of appropriate biopharmaceutical properties, such as the determination of cytotoxicity in cells or the inhibition of certain targets or channels to determine potential toxicity, is within the knowledge of one of ordinary skill in the art.

[0444] The present invention is not limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and all that are functionally equivalent are within the scope of the present invention. Various modifications to the models, methods, and lifecycle approaches of the present invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description and teachings, and are likewise intended to be included within the scope of the present invention. Such modifications or other embodiments can be made without departing from the true scope and spirit of the invention.

[0445] [Table I]

[0446]

Table II

[0447]

Table III

Claims

1. 1. An ICD prodrug composition comprising: (iv) a drug moiety; and (v) a lipid moiety; and (vi) a linking unit ("LU"); Including, the drug moiety comprises an agent that induces ICD, and the LU conjugates the drug moiety to the lipid moiety; ICD Prodrug Compositions.

2. 2. The ICD prodrug of claim 1, wherein the drug moiety comprises the chemical structure set forth as IC1.

3. The ICD prodrug of claim 1 , wherein said LU is a hydrazone linker.

4. 2. The ICD prodrug of claim 1, wherein the lipid moiety comprises a lipid set forth in Table III.

5. 2. The ICD prodrug of claim 1, wherein the lipid moiety comprises stearic acid.

6. The drug portion comprises the chemical structure described as IC1, the lipid portion comprises stearic acid, and the compound has the following chemical structure: 【Chemical 27】 2. The ICD prodrug of claim 1 having the formula:

7. 1. An ICD prodrug composition comprising: (iv) a drug moiety comprising IC1; and (v) a lipid portion comprising stearic acid; (vi) LU, which comprises a hydrazone linker; 1. An ICD prodrug composition comprising:

8. The chemical structure: 【Chemistry 28】 8. The ICD prodrug composition of claim 7, having the formula:

9. A nanocarrier comprising an ICD prodrug, which releases an agent that induces immunogenic cell death (ICD) after cleavage of LU.

10. The nanocarrier of claim 9 , wherein the LU is a hydrazone linker.

11. 10. The nanocarrier of claim 9, further comprising a helper lipid as set forth in Table II.

12. A kit comprising the nanocarrier according to any one of claims 9 to 11.

13. The nanocarrier of claim 9, wherein the nanocarrier is a solid lipid nanoparticle (SLNP).

14. The SLNP of claim 13, wherein the ICD prodrug comprises IC1 and is referred to as SLNP-IC1.

15. A solid lipid nanoparticle (SLNP) comprising the IC1 prodrug of claim 8.

16. The SLNP of claim 15, designated SLNP-IC1.

17. The SLNP of claim 15, co-formulated with TR12.

18. The SLNP of claim 15, which is co-formulated with RGD.

19. The SLNP of claim 15, further comprising IC1 co-formulated with TR12 (referred to as SLNP-IC1-TR12).

20. The SLNP of claim 15, further comprising IC1 co-formulated with RGD (referred to as SLNP-IC1-RGD).